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SUMMARY 
 
Epstein-Barr virus (EBV) immortalises resting B-lymphocytes to lymphoblastoid 
cell lines (LCLs) and is associated with many cancers. The cell-cycle regulator 
response gene to complement 32 (RGC-32) is upregulated in EBV-infected 
cells, binds the mitotic kinases CDK1 and PLK1 and disrupted cell cycle 
checkpoints. RGC-32 may therefore play a role in EBV-mediated cell-cycle 
deregulation. RGC-32 has no homology with any other known proteins, so 
affinity-tagged forms of RGC-32 were expressed in E.coli for structure-function 
studies. Replacing a polyhistidine tag with a glutathione S-Transferase (GST) 
tag and optimising expression conditions improved RGC-32 solubility. Purified 
soluble RGC-32 was produced for structural studies, but no crystals were 
obtained. Using the GST-RGC-32 fusion protein I showed that RGC-32 
interacts with CDK1, Plk1 and the kinetochore component Spc24 from B-cell 
lysates. Interestingly, RGC-32 did not interact with cyclin B1, suggesting that it 
may activate CDK1 in a cyclin-independent manner. Mapping the regions of 
interaction between RGC-32 and CDK1 and Plk1 revealed these kinases bind 
to different but adjacent regions of RGC-32. To investigate the role of RGC-32 
in cell cycle disruption by EBV, I made a series of cell-lines stably expressing 
inducible RGC-32 constructs and RGC-32 disrupted G2/M checkpoint in an 
additional B-cell line. Investigating the mechanism of RGC-32 transcription 
control in EBV-infected cells demonstrated that although EBV transcription 
factors bind to intronic regions of the RGC-32 gene, no regulation was detected 
in reporter assay. These data reveal a novel aspect of CDK1 activation by 
RGC-32, identify the sites of protein-protein interactions and provide new cell-
lines for further investigation of RGC-32 function. 
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1 Introduction 
1.1 Cell cycle 
Cell division describes the process by which organisms precisely duplicate the 
DNA in the chromosomes and pass it on to two daughter cells.  It is divided into 
four phases in eukaryotes G1, S, M, G2 and a resting phase, G0 (Figure 1-1). In 
synthesis (S) phase, the DNA in the cell is replicated and chromosomes are 
duplicated from single chromatids to double (sister) chromatids. In mitosis (M) 
phase the cell is divided into two daughter cells followed by nuclear division. M 
phase is a complicated process which is composed of prophase, prometaphase, 
metaphase, anaphase and telophase. During prophase, chromatin condenses 
into chromosomes and in prometaphase the nuclear membrane breaks down. 
Chromosomes then line up along the equatorial plate in metaphase, separate at 
centromeres and sister chromatids then move to the cell poles in anaphase. 
During telophase a new nuclear membrane is formed and chromosomes 
decondense into chromatin. S and M phases are separated by two gap phases 
(G1 and G2) in which cells prepare for DNA replication or mitosis. 
 
1.1.1 Cell cycle control system 
Three main checkpoints in G1, G2 and mitosis make sure that appropriate 
processes in the cell cycle occur in the proper sequence, i.e. prevent progress 
into the next phase if the process is not completed. The key components of the 
cell cycle control system are cyclin-dependent kinases (CDKs) and cyclins  
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Figure 1-1 Cell cycle overview.  
The cell cycle is divided into four phases (G1, S, G2 and M) and a resting phase G0. The CDK/Cyclin 
complexes, Plk1 and the status of Rb phosphorylation regulate progression of cells through the different 
phases of the cell cycle.  
 
 
 
 
 
1-3 
 
which are activated throughout the cell cycle and regulate the transition of each 
cell from one cell cycle state to the next (Pines 1995) (Figure 1-1). 
 
1.1.2 CDK1 and Cyclin B1 
Original investigations into genes which control cell size at cell division (Nurse 
1990) and subsequent research on amphibian oocytes led to the identification 
of M phase-promoting factor (MPF) (Smith and Ecker 1971, Masui and Markert 
1971). Later work with Xenopus oocytes revealed the components of MPF to be 
CDK1 (Gautier et al. 1988, Arion et al. 1988, Dunphy et al. 1988, Labbe et al. 
1988) and cyclin B (Gautier et al. 1990, Labbe et al. 1989). The CDK1/cyclin B1 
complex remains inactive until late G2, although cyclin B1 is expressed in late S 
and G2 phases (Pines and Hunter 1989, Nurse 1990, Maller 1991).  
 
In normal cells, the assembly of CDK1 and cyclin B1 only produces a partly 
active complex and its full activity is reached through phosphorylation at 
Threonine 161 in CDK1 by CAK (cdk-activating kinase) (Solomon, Lee and 
Kirschner 1992), a complex of CDK7 and cyclin H. CAK activity is constant 
throughout the cell cycle (Tassan et al. 1994, Bartkova, Zemanova and Bartek 
1996). CDK1 is however inactivated by phosphorylation on Threonine 14 and 
Tyrosine 15 by the kinases Wee1 and Myt1 (McGowan and Russell 1993, 
Mueller et al. 1995), even in the presence of CAK-catalyzed activating 
phosphorylation. The activities of both Wee1 and Myt1 are regulated by 
phosphorylation and localization (McGowan and Russell 1995, Watanabe, 
Broome and Hunter 1995, Wang et al. 2000, Liu et al. 1997). At the G2/M 
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transition, inhibitory phosphorylation on Threonine-14 and Tyrosine-15 of CDK1 
is removed by the phosphatase CDC25 which allows cells to enter mitosis 
(Kumagai and Dunphy 1991) (Figure 1-2). 
 
In addition, the activity of the CDK1/cyclin B1 complex is regulated by cellular 
localization (Hagting et al. 1998, Yang et al. 1998). In interphase, CDK1/cyclin 
B1 complexes localize to the cytoplasm (Pines and Hunter 1991, Ookata et al. 
1993, Bailly et al. 1992) and during late prophase most CDK1/cyclin B1 
complexes are translocated from cytoplasm to the nucleus (Hagting et al. 1999, 
Clute and Pines 1999). The phosphorylation of Threonine 161 by CAK is 
achieved in the nucleus where CAK is localized (Obaya and Sedivy 2002) and 
some evidence indicates that CDC25C is also localized in the cytoplasm during 
interphase and moves to the nucleus during prophase (Seki et al. 1992, Heald, 
McLoughlin and McKeon 1993, Kumagai and Dunphy 1991, Dalal et al. 1999, 
Graves et al. 2000). 
 
If DNA is damaged, the G2/M checkpoint is activated. Ataxia telangiectesia 
mutated (ATM) and ataxia telangiectasia and Rad3-related protein (ATR), two 
central components of the DNA damage response are activated (Elledge 1996). 
ATM is a 350 kDa protein and has homology to the phosphoinositide 3-kinases 
(Shiloh 1997, Perry and Kleckner 2003, Bakkenist and Kastan 2003, Savitsky et 
al. 1995). ATR is a 303 kDa protein with homology to other phosphoinositide 3-
kinase-like kinase (PIKK) family members (Sancar et al. 2004). As downstream  
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Figure 1-2. G2/M checkpoint.  
In absence of cytotoxic stress, inhibitory phosphorylation on Threonine-14 and Tyrosine-15 of CDK1 is 
removed by the phosphatase CDC25 which allows cells to enter mitosis at the G2/M transition. In the 
presence of cytotoxic stress downstream activators of ATR and ATM, chk1 and chk2 can phosphorylate 
CDC25C on Serine-216 and this phosphorylation can result in CDC25 degradation, resulting in a failure to 
dephosphorylate CDK1 on Threonine-14 and Tyrosine-15. So CDC25 cannot remove those two inhibitory 
phosphates from CDK1 which leads to G2 arrest.  
 
 
 
 
 
 
  
Doubl  strand DNA break 
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activators of ATR and ATM, chk1 and chk2 (Abraham 2001, Matsuoka, Huang 
and Elledge 1998)can phosphorylate CDC25C on Serine-216 and this 
phosphorylation can result in CDC25 degradation, resulting in a failure to 
dephosphorylate CDK1 on Threonine-14 and Tyrosine-15 (Matsuoka et al. 1998, 
Henle, Henle and Diehl 1968). The ATM-Chk2-CDC25 pathway responses to 
double-stranded DNA breaks caused by ionizing radiation and UV light 
exposure and the ATR-Chk1-CDC25 pathway responses to single-strand DNA 
breaks caused by replication errors and hydroxyurea. So once DNA is damaged, 
either the ATM-Chk2-CDC25 or the ATR-Chk1-CDC25 pathway is activated to 
arrest the cell cycle in G2 (Zhao and Piwnica-Worms 2001, Xu et al. 2002, 
Brown and Baltimore 2003). 
 
1.1.3 Plk1 
The polo gene was first discovered in Drosophila (Sunkel and Glover 1988) and 
five Plks (Plk1-5) have been identified in humans (Glover, Hagan and Tavares 
1998, Andrysik et al. 2010). The human Plk1 was cloned in 1994 and is 
expressed highly at the mRNA level in tissues that contain dividing cells.  Plk1 
protein level changes in cell cycle, and are highest in mitosis (Golsteyn et al. 
1994).  
 
Aurora A can activate Plk1 by phosphorylating threonine 210 in the activation 
loop in the G2 phase, but only when Plk1 binds to Bora, an aurora A kinase 
activator in cell cycle (Macurek et al. 2008, Jang et al. 2002, Seki et al. 2008). 
The exact mechanism of how Bora and Plk1 interact is still not clear, but one 
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possibility is that the interaction is triggered through the phosphorylation of Bora 
by CDK1 (Chan et al. 2008). During the G2/M transition, Plk1 phosphorylates 
CDK1/Cyclin B and Cdc25 leading to mitotic entry (Kumagai and Dunphy 1996). 
So there is controlling loop between CDK1 and Plk1.  
 
When DNA is damaged, activation of the DNA damage pathway ATM/ATR-
Chk2/1-p53 results in cell cycle arrest and Plk1 inactivation (Smits et al. 2000, 
Taylor and Stark 2001). The first Plk1 substrate that is involved in DNA damage 
recovery is Claspin which bridges ATR and Chk1 (Mamely et al. 2006, 
Peschiaroli et al. 2006). Claspin is phosphorylated by Plk1 and this 
phosphorylation causes degradation of claspin, which is necessary for the 
termination of the DNA replication checkpoint which allows cells to go into 
mitosis (Mailand et al. 2006, Mamely et al. 2006, Peschiaroli et al. 2006). 
 
1.1.4 Spc24-25 
Core components of the kinetochore are the constitutive centromere associated 
network (CCAN) and the Knl1-Mis12 complex-Ndc80 complex (KMN) which 
bind to centromeric DNA and microtubule respectively and both of them are 
conserved across eukaryotes (McAinsh and Meraldi 2011, Cheeseman et al. 
2006). The KMN network (Figure 1-3) includes kinetochore null 1 (Knl1), the 
four-protein Mis segregation 12 (Mis12) complex and the four-protein nuclear 
division cycle 80 (Ndc80) complex (reviewed in (Foley and Kapoor 2013). The 
Ndc80 complex is a heterotetramer comprised of Ndc80 protein, nuclear 
filamentous 2 (Nuf2), spindle pole component 24 and 25 (Spc24-25) (reviewed  
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Figure 1-3. The KMN network.  
The KMN network (Figure 1-3 d) is a kinetochore protein complexes. It is formed by kinetochore null 1 
(Knl1, Figure 1-3 a), the mis-segregation 12 (Mis12) complex (Figure 1-3 b) and the nuclear division cycle 
80 (Ndc80) Complex (Figure 1-3 c). This figure was taken from (Godek et al., 2015). 
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in (Foley and Kapoor 2013). CCAN localises to the inner kinetochore and KMN 
network localises to the outer kinetochore (Cheeseman and Desai 2008).  
 
The four proteins in Ndc80 complex form a rod like structure and Ndc80 and 
Nuf2 form a complex which localises to the outer kinetochore and Spc24-25 
form a complex which localises to the inner kinetochore (Cheeseman and Desai 
2008). The Ndc80 complex is important for the attachment of kinetochore to 
microtubule and Spc24-25 interacts with yeast histone-fold protein Cnn1 
(human homologue CENP-T) illustrating how this connection links microtubule 
to chromosome (Malvezzi et al. 2013). Cnn1 binds to the hydrophobic pocket 
located in the globular domain of Spc24-25 (Malvezzi et al. 2013).  
 
1.2 EBV 
Epstein-Barr virus (EBV) was originally discovered in 1964 in B lymphocytes 
cultured from an African Burkitt’s lymphoma (BL) (Epstein, Achong and Barr 
1964) and was the first herpes virus to have its genome completely cloned and 
sequenced. The virus causes a latent and persistent infection and is a gamma 
herpes virus known to be associated with several cancers such as Burkitt’s 
lymphoma (BL), Hodgkin’s lymphoma (HL), Nasopharyngeal carcinoma (NPC) 
and post-transplant lymphoproliferative disease (PTLD) (reviewed in Crawford 
2001). In vivo, primary EBV infection usually occurs during childhood via saliva 
(Niederman et al. 1976) in about 90% of the world-wide population and is 
asymptomatic (De Matteo et al. 2003, Henle et al. 1969). However, infectious 
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mononucleosis (IM) can develop if primary infection occurs in adolescence 
(Niederman et al. 1968).  
 
EBV is able to infect and transform B lymphocytes but can also infect epithelial 
cells and in some situations may infect T cells and natural killer cells (Kieff and 
Rickinson, 2007). EBV attaches to B cells due to a high-affinity interaction 
between major viral envelope glycoprotein gp350 and complement receptor 
CD21 (also known as CR2) on the B cell (Nemerow et al. 1985), then through 
the binding of a second glycoprotein gp42 to human leukocyte antigen (HLA) 
class II molecules as a co-receptor (Borza and Hutt-Fletcher 2002). After the 
virus attaches to the B cell surface, the virus fuses its envelope to the vesicle 
membrane through CD21 (Miller and Hutt-Fletcher 1992).  The EBV DNA is 
found to occur after uncoating of the virion 12-16 hours after infection when 
coinciding with early latent viral gene expression (Adams and Lindahl 1975, 
Hurley and Thorley-Lawson 1988). Infection of epithelial cells takes place at the 
cell surface (Miller and Hutt-Fletcher 1992) and is thought to happen in a 
gp350-dependent or -independent manner (Fingeroth et al., 1999; Maruo et al., 
2001). Recently it has been called transfer infection in which EBV infects 
epithelial cells by first binding to resting B cells which act as a transfer vehicle 
(Shannon-Lowe et al. 2006).  
 
Two types of EBV has been described as EBV type 1 (EBV-1) and 2 (EBV-2) 
and the major difference between them is only 64% of the gene and 53% of the 
amino acids sequence of EBNA 2 is conserved between types (Adldinger et al. 
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1985). EBV-2 infection rarely happens in Western Europe and USA, but is 
common in Africa (Rowe et al. 1989, Young et al. 1987, Zimber et al. 1986).  
1.2.1 EBV genome 
The EBV genome is a linear 170 kb double-stranded DNA in the virion and 
becomes closed circular episome after infection (Hurley and Thorley-Lawson, 
1988; Lindahl et al., 1976). In vitro, EBV can transform resting B cells to 
generate latently infected lymphoblastoid cell lines (LCLs) which express a 
limited set of viral genes, encoding six EBV nuclear antigens (EBNA1, 2 3A, 3B, 
3C and -LP) and three latent membrane proteins (LMPs 1, 2A and 2B) (Figure 
1-4) (Young and Rickinson 2004). EBV encoded RNAs (EBER1 and 2) which 
do not have a polyadenylated tail, so remain as untranslated RNA and are 
expressed in all forms of latency (Young and Rickinson 2004). EBV encodes 
multiple microRNAs (miRNA) from two independent transcripts, BamHIA 
rightward transcripts (BARTs) and BamHI rightward reading frame 1 (BHRF1) 
(Young and Rickinson 2004). This pattern of latent EBV gene expression which 
is activated only in B-cell infection is defined as latency III (reviewed in Young 
and Rickinson, 2004). EBV displays two other latency programmes in various 
EBV-related malignancies and in healthy infected hosts characterised by more 
restricted latent gene expression patterns (reviewed by (Shah and Young 2009): 
latency I and latency II. Latency I is associated with expression of EBNA 1 and 
Epstein-Barr virus Encoded RNAs (EBER 1 and EBER 2). Latency II is 
associated with expression of EBNA1, LMP 1, 2A, 2B and Epstein-Barr virus 
Encoded RNAs (EBER 1 and EBER 2) (summarised in Table 1-1).  
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Figure 1-4. Location and transcription of the EBV latent genes on the double-stranded 
viral DNA episome.  
The red circle line represents EBV transcription during latency III in which all the EBNAs are transcribed 
from promoter C or W. The blue circle line represents EBV transcription during latency I and II in which 
EBNA1 is transcribed from promoter Q during latency I and II. The yellow shows the origin of plasmid 
replication (oriP). The purple arrows represent exons encoding the latent proteins and the direction in 
which the genes are transcribed. The two yellow arrows on the top represent the non-polyadenylated 
RNAs EBER1 and 2 (Murray and Young 2001).  
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  Latency 0 Latency I Latency II Latency III 
Gene  
expressed 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
EBNA 1 (Qp) 
EBER 1 
EBER 2 
  
  
  
  
  
  
  
  
EBNA 1 (Qp) 
LMP 1 
LMP 2A 
LMP 2B 
EBER 1 
EBER 2 
  
  
  
  
  
EBNA 1 (Cp) 
EBNA 2 
EBNA 3A 
EBNA 3B 
EBNA 3C 
EBNA LP 
LMP 1 
LMP 2A 
LMP 2B 
EBER 1 
EBER 2 
Site in vivo 
 
 
 
Periphery 
resting 
memory B 
cells 
Periphery 
dividing 
memory B 
cells 
Tonsil GC B cells Tonsil naive 
B cells 
 
 
 Diseases   
  
  
  
BL 
  
  
  
HD, NC, 
T cell lymphomas 
  
AIDS- 
associated  
lymphomas, 
PTLD 
  
  
  
 
Table 1-1. EBV gene expression pattern during different states of infection and tumours 
(modified from (Thorley-Lawson 2015)). 
In latency 0, no latent EBV protein is expressed. In latency I, EBNA 1, EBER 1 and 2 are expressed and 
this pattern of expression is found in Burkitt’s lymphoma group I. In latency II, EBNA 1, LMP 1, 2A and 2B 
are expressed and this pattern of expression is found in Hodgkin’s disease (HD), nasopharyngeal 
carcinoma (NC) and T cell lymphomas. In latency III, all latency EBV genes are expressed and this pattern 
of expression is found in AIDS-associated lymphomas and post-transplant lymphoproliferative disease 
(PTLD).  
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The EBV genome contains different promoters which contribute to the 
expression of the latent EBV proteins (reviewed in (Young and Rickinson 2004). 
The C promoter (Cp) and the W promoter (Wp) are both located within the EBV 
major internal repeat (IR-1). The Q promoter (Qp) only expresses EBNA 1 
transcript. The activation of Wp by B cell transcription factors on initial infection 
causes the expression of EBNA2 and EBNA LP (Bell et al. 1998); Kirby et al., 
2000; (Walls and Perricaudet 1991, Kirby, Rickinson and Bell 2000). Within 36 
hours after infection, Cp activation by EBNA 2 switches promoter usage from 
Wp to Cp which leads to the expression of all EBNA proteins ((Puglielli, 
Woisetschlaeger and Speck 1996); (Woisetschlaeger et al. 1990). Qp drives the 
expression of EBNA 1 in the absence of Cp activation and EBNA 2 expression 
((Nonkwelo et al. 1996); (Schaefer, Strominger and Speck 1995). In EBV-
infected B-cells, Cp and promoters of the vial LMP1, 2A and 2B genes is 
activated by EBNA 2 (Abbot et al. 1990, Fahraeus et al. 1990, Ghosh and Kieff 
1990, Jin and Speck 1992, Sung et al. 1991, Wang et al. 1990). In absence of 
EBNA 2 in latency II, the expression of LMP1 is maintained by cytokine-induced 
activity of signal transducers and activators of transcription (STAT) and also 
transcription factors of the CCAAT enhancer-binding protein (C/EBP) family 
(Chen et al. 2001, Chen et al. 2003, Kis et al. 2006, Kis et al. 2010, Kis et al. 
2011, Noda et al. 2011). The EBNA 3 genes (EBNA 3A, 3B and 3C) are 
arranged in tandem sequence in the EBV genome and transcribed as 
alternatively spliced tanscripts from the very long mRNA initiated by the Cp 
(White et al. 2010) which is active in EBV transformed lymphoblastoid cell lines 
(LCLs) but blocked in some EBV-associated cancers through hypermethylation 
(reviewed in (Allday, Bazot and White 2015). 
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More than 90% of the human population are infected by EBV (Henle et al. 1969) 
carrying the virus as a life-long persistent latent infection in B lymphocytes 
(Babcock et al. 1998, Thorley-Lawson, Miyashita and Khan 1996) with virus 
production into the saliva (Niederman et al. 1976, Yao, Rickinson and Epstein 
1985).  
1.2.2 EBV infection in vivo 
1.2.2.1 EBV infection in healthy hosts 
How EBV infects and persists in the host is not fully understood, but a proposed 
model has been described as a dynamic equilibrium between the immune 
system response and the different states of infection (Figure 1-5) (Young and 
Rickinson 2004). In primary infection, EBV infects naive B cells and transforms 
them to B blasts expressing all latent EBV proteins (latency III) (Babcock et al. 
1999). The B blasts differentiate to germinal centre cells which display EBNA 1, 
LMP1 and 2A (latency II) probably because the expression of EBNA 2 blocks 
the differentiation of B cells to memory cells and therefore it is silenced (Polack 
et al. 1996). The germinal centre cells then differentiate to resting viral-genome-
positive memory B cells in which all latent gene expression is turned off (latency 
0) (Babcock et al. 1999). In the rarely dividing memory B cells, expression of 
EBNA 1 from the Q promoter is observed (latency I) to make sure the episome 
is not lost during cell division in hosts (Davenport and Pagano 1999, Hochberg 
et al. 2004).  
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Figure 1-5. In vivo model of interactions between EBV and host cells (Young and 
Rickinson 2004).  
a. Primary infection. Virus establishes lytic replication in the oropharynx then spreads to the lymphoid 
tissues as a latent (latency III) growth-transforming infection of B cells. Many proliferating cells are 
removed by the latent-antigen-specific primary T-cell response, but some escape by downregulating 
antigen expression and establishing a reservoir of resting viral-genome-positive memory B cells (latency 0) 
in which viral antigen expression is mostly suppressed. b. Persistent infection. The reservoir of EBV-
infected memory B cells migrate and differentiate under physiological control. These EBV-infected cells 
might be recruited into germinal centre, after which either re-enter the reservoir as memory cells or move 
to mucosal sites in the oropharynx and activate the viral lytic cycle (reviewed in (Young and Rickinson 
2004).  
 
1.2.2.2 Latent EBV gene expression in diseases 
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Unlike other herpes viruses, EBV has the unique ability to transform resting B 
cells to immortal latently infected lymphoblastoid cell lines (LCLs) in vitro 
indicating its tumourigenic ability (Pope, Horne and Scott 1968). Different 
patterns of latent EBV gene expression are observed in EBV-related diseases 
(summarised in Table 1-1). In latency I, only EBNA 1 and two EBERs are 
expressed and this pattern is observed in many Burkitt’s lymphoma tumour cells 
(Rowe et al. 1987, Brooks et al. 1993). In Wp-restricted Burktt’s lymphoma, 
EBNA 1, 3A, 3B, 3C and -LP are expressed in the absence of ENBA 2 and the 
LMPs (Kelly et al. 2006). In latency II, EBNA 1, all three LMPs and the two 
EBERs are expressed and this pattern is detected in Hodgkin’s disease, 
nasopharyngeal carcinoma and T cell lymphomas (Brooks et al. 1992, Deacon 
et al. 1993, Chen et al. 1993). In latency III, all latency EBV genes including 
EBNA 1, 2, 3A, 3B, 3C, LP, all three LMPs and the two EBERs are expressed 
and this pattern is found in AIDS-associated lymphomas and post-transplant 
lymphoproliferative disease (Young et al. 1989, Gratama et al. 1991). 
 
1.2.3 EBV latent proteins 
1.2.3.1 EBNA 1 
Epstein-Barr nuclear antigen 1 (EBNA1) is expressed in all patterns of EBV 
latency and it was the first latency protein identified by anti-complement 
immunofluorescence in EBV-immortalized cells (Reedman and Klein 1973). It is 
necessary for B lymphocyte transformation (Lee, Diamond and Yates 1999). 
EBNA 1 is 641 amino acids in length from the prototype EBV type 1 strain B95-
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8 (see section 1.2 EBV) and has a molecular weight of approximately 76 kD on 
SDS-PAGE gels.  
 
EBNA 1 plays a key role in replication and mitotic segregation of EBV episome 
to ensure vial persistence in latent infection and also activates transcription of 
other EBV latency genes (reviewed in (Frappier 2015). EBNA 1 is the only viral 
protein required for the replication of the origin of latent DNA replication (oriP) 
(Figure 1-4) (Yates, Warren and Sugden 1985). EBV episomes replicate only 
once in each cell cycle alongside host DNA (Yates and Guan 1991) and the 
dyad symmetry (DS) element, one of two functional elemens in oriP (Reisman, 
Yates and Sugden 1985), is essential and sufficient for plasmid replication in 
the presence of EBNA 1 (Wysokenski and Yates 1989, Harrison, Fisenne and 
Hearing 1994, Yates, Camiolo and Bashaw 2000). The central Gly-Arg repeat 
region of EBNA 1 (325-376) binding to its recognition sites in the family of 
repeats (FR), the other functional elements in oriP, is necessary for its 
segregation function (Shire et al. 1999). EBNA 1 plays a role in inducing the 
expression of latency genes in latent infection by activating expression from the 
viral Cp and LMP promoters (Sugden and Warren 1989, Gahn and Sugden 
1995). The 65-83 N-terminal sequence (Wu, Kapoor and Frappier 2002, 
Kennedy and Sugden 2003) and the central Gly-Arg repeat region are required 
for transcriptional activation (Ceccarelli and Frappier 2000, Wang et al. 1997, 
Van Scoy et al. 2000).  
 
1-19 
 
Importantly EBNA 1 can auto-downregulate its own expression by binding to 
two sites located downstream of the Q promoter (Sample, Henson and Sample 
1992). This autoregulation mechanism functions to reduce EBNA 1 expression 
when its level is high, since it will only bind to the two Qp sites when its 
expression is high enough to saturate the DS and FR elements first, due to the 
high affinity for these elements than the two Qp sites (Jones, Hayward and 
Rawlins 1989, Ambinder et al. 1990).  
 
EBNA 1 has been shown to play a role in regulating cellular protein function. 
The cellular ubiquitin-specific protease USP7, also known as HAUSP, is one of 
several cellular proteins identified to be bound by EBNA 1 (Holowaty et al. 2003, 
Malik-Soni and Frappier 2012). The expression of EBNA 1, but not a USP7-
binding mutant of EBNA 1 in U2OS cells has been reported to reduce the 
accumulation of p53 in response to DNA damage and apoptosis (Saridakis et al. 
2005). Similar results have been shown that EBNA 1 expression in CNE2 NPC 
cells decreased the accumulation of p53 in response to DNA damage 
(Sivachandran, Sarkari and Frappier 2008). These findings suggest that EBNA 
1 might modulate p53 to promote cell survival in EBV-infected epithelial cells. 
EBNA 1 has been reported to affect several signalling pathways. First it 
increases the expression of STAT1 in three different carcinoma cell lines (Wood 
et al. 2007, Kim and Lee 2007). Second, its expression decreases the 
expression of TGF-β-responsive genes implying that EBNA 1 is involved in 
TGF-β signalling (Wood et al. 2007, Kim and Lee 2007). Third, EBNA 1 inhibits 
NF-κB activity and DNA binding in carcinoma cell lines (Valentine et al. 2010). 
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1.2.3.2 EBNA 2 
EBNA 2 is a 487 amino acid protein in the prototype EBV type 1 strain B95-8 
(see section 1.2 EBV) (Baer et al. 1984, Skare et al. 1982) which has a 
molecular weight of about 84 kDa on SDS-PAGE gels. Transcription of EBNA 2 
initiates first from Wp following primary infection of B cells, then generally 
switches to Cp, which is upstream of Wp, activated during later stages of 
infection or in LCLs (Alfieri, Birkenbach and Kieff 1991, Bodescot, Perricaudet 
and Farrell 1987, Woisetschlaeger et al. 1990, Woisetschlaeger et al. 1991).  
 
EBNA 2 is essential for B cell transformation. EBV strain P3HR-1 which has a 
deletion of EBNA2 has no B cell immortalizing capacity (Miller et al. 1974) and it 
is able to transform primary B cells when the cloning fragment containing the 
EBNA 2 gene is reconstituted into the EBV genome (Cohen et al. 1989, 
Hammerschmidt and Sugden 1989). EBV-1 and EBV-2, two main types of EBV, 
differ in their ability to immortalise primary B cells (Adldinger et al. 1985, 
Dambaugh et al. 1984) due to mainly difference of sequence in the C terminus 
of them (Tzellos et al. 2014, Tzellos and Farrell 2012) and they due to the 
difference of sequence in the EBNA 2. EBNA 2 is not expressed in latently 
infected memory B cells of healthy hosts or EBV-associated malignancies of 
immunocompetent patients, such as Burkitt’s lymphoma or Hodgkin’s disease 
(reviewed in (Bornkamm and Hammerschmidt 2001, Macsween and Crawford 
2003).  
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Instead binding to DNA directly, EBNA 2 utilises RBP-Jκ, the cellular Notch-
pathway adapter protein CBF1, to bind upstream of and activate the latent Cp 
(Sung et al. 1991, Jin and Speck 1992), LMP1, 2A and 2B (Fahraeus et al. 
1990, Ghosh and Kieff 1990, Wang et al. 1990). EBNA 2 minimal binding 
domain with RBP-Jκ is mapped at aa 318-327 on EBNA 2 (Ling and Hayward 
1995). In addition to viral gene, EBNA 2 is found to regulate many cellular 
genes by microarrays analysis using EBNA 2 conditional LCLs or EBV negative 
BL cells expressing only EBNA 2 (Cahir-McFarland et al. 2004, Thompson et al. 
1999, Maier et al. 2006). The cellular EBNA 2 targets include CD21 (Cordier et 
al. 1990), the B cell activation marker CD23 (Wang et al. 1987), the proto-
oncogene Myc (Kaiser et al. 1999), the B cell transcription factor RUNX 3 
(Spender et al. 2002) and the G1 Cyclin D2 (Sinclair et al. 1994).  
 
1.2.3.3 EBNA-LP 
Transcription of EBNA leader protein (-LP) is required for B cell immortalisation 
(Allan et al. 1992, Mannick et al. 1991). EBNA-LP co-activate EBNA 2 during 
infection as Chloramphenicol acetyltransferase (CAT) reporter assays 
containing upstream Cp or LMP1p are enhanced by co-expression of EBNA 2 
and -LP by 10-30 fold compared to expression of EBNA 2 alone, but EBNA-LP 
repressed the transcription from LMP1p and Cp in the absence of EBNA 2 
(Harada and Kieff 1997). In addition to viral genes, EBNA-LP has been shown 
to co-stimulate EBNA 2-dependent transcription of the Cyclin D2 gene (Sinclair 
et al. 1994) and the transcription factor HES1 (Portal et al. 2011).  
 
1-22 
 
EBNA-LP is a phosphoprotein (Petti, Sample and Kieff 1990). Phosphorylation 
of EBNA-LP, occurs predominately on serine residues and is detected 
throughout the cell cycle.  EBNA-LP is hypophosphorylated during G1/S and 
hyperphosphorylated during G2/M (Kitay and Rowe 1996). Serine 35 in EBNA-
LP is a predicted CDK1 site and phosphorylation of it is crucial for EBNA-LP 
mediated transcriptional function (Peng et al. 2000a, Peng, Tan and Ling 2000b, 
McCann et al. 2001, Yokoyama et al. 2001). 
 
1.2.3.4 EBNA3 family  
The EBNA3 family of proteins was first detected as an extra 142 kD band along 
with other previously identified latent proteins EBNA1, 2, and LMP1 by Western 
blotting using human sera from rheumatoid arthritis patients and normal EBV-
infected people (Hennessy, Fennewald and Kieff 1985, Rickinson and Moss 
1997b). It has been shown that EBNA3A and EBNA3C are necessary for B-cell 
immortalization (Tomkinson, Robertson and Kieff 1993), but EBNA3B is not 
(Tomkinson and Kieff 1992). However EBNA3B is one of the main targets in 
immortalized cells to be recognized by cytotoxic T cells (Rickinson and Moss 
1997a) and has been reported as a virus-encoded tumour suppressor because 
its inactivation promotes immune evasion and virus-driven lymphomagenesis 
(White et al. 2012) 
 
1.2.3.4.1 Transcriptional regulation by the EBNA 3s 
EBNA3 proteins function as transcriptional regulators by interacting with many 
cellular DNA binding proteins or other transcription factors instead of directly 
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binding to DNA (reviewed in (Bhattacharjee et al. 2016). All three EBNA3 
proteins are proved to interact with the RBP-Jκ and the interacting domains 
overlap with the most highly conserved domain amino acids 90-320 (Robertson 
et al. 1995, Robertson, Lin and Kieff 1996, Waltzer et al. 1996). Interestingly all 
three EBNA 3 proteins can bind RBP-Jκ and repress EBNA 2-activated 
transcription by destablilising the binding of RBP-Jκ to DNA (Johannsen et al. 
1996, Waltzer et al. 1996). EBNA 2 can activate Cp via RBP-Jκ and mutation in 
the RBP-Jκ binding site lead to the loss of the transforming ability of EBV 
(Fuentes-Panana et al. 2000, Sung et al. 1991, Yalamanchili et al. 1994). So 
EBNA 3 proteins form a negative feedback loop which may lead to the 
abrogation of EBNA 2 upregulation of EBNA 3 transcription. The interaction 
region of each EBNA 2 with RBP-Jκ is located in the middle of the homology 
domain between 170-221 aa for EBNA 3A, 176-227 aa for EBNA 3B and 180-
231 aa for EBNA 3C (Bourillot et al. 1998, Calderwood et al. 2011, Dalbies-Tran 
et al. 2001, Lee et al. 2009, Maruo et al. 2005, Maruo et al. 2009, Robertson et 
al. 1996). Also all EBNA3 proteins are reported to repress the activation of 
LMP1 and LMP2 by EBNA 2 (Le Roux et al. 1994, Waltzer et al. 1996). 
Inactivation of EBNA 3A and 3C does not increase the activation of some target 
promoters containing RBP-Jκ binding sites by EBNA 2 in infected cells (Maruo 
et al. 2005, Maruo et al. 2009).  
 
EBNA 3A and 3C, but not EBNA 3B, interact with the co-repressor carboxy-
terminal binding protein (CtBP) (Hickabottom et al. 2002, Touitou et al. 2001) 
which is identified as one of a highly conserved family of co-repressors of 
transcription (Chinnadurai 2007). There are two transcription factors: CtBP1 and 
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CtBP2 which share substantial sequence homology (Chinnadurai 2002, 
Chinnadurai 2009). EBNA 3A contains two non-consensus CtBP binding motifs, 
located at the C-terminal region, ALDLS (aa 857-861) and VLDLS (aa 886-890) 
(Hickabottom et al. 2002). The PLDLS (aa 728-732) motif in the C-terminal of 
EBNA 3C is essential and sufficient for EBNA 3C to interact with CtBP1 
(Touitou et al. 2001). Although the requirement for CtBP binding is not yet 
understood, it has been shown that C terminus of EBNA 3C, specifically the 
PLDLS CtBP-binding site, is essential to rescue proliferation in EBNA 3C-
conditional LCLs culture without the activator (Lee et al. 2009).  
 
The finding that expression of both EBNA 3A and 3C is necessary to repress 
the transcription of BCL2L11 (BIM) shows the first evidence that EBNA 3A and 
3C can cooperate to regulate host cell genes using EBNA 3 knockout 
recombinant B95.8-derived EBVs to infect EBV-negative BL31 BL-derived cells 
(Anderton et al. 2008).  Bcl2-interacting mediator (BIM) is a pro-apoptotic 
member of the BH (BCL2 homology) 3-only family and is encoded by the 
BCL2L11 gene (O'Connor et al. 1998). BIM expression reduction has been 
found very soon after EBV infection in cultured B cells (Anderton et al. 2008, 
Skalska et al. 2013). Also EBNA 3C is necessary to repress the expression of 
the CDK inhibitor p16INK4a shown by using a recombinant Akata EBV encoding a 
conditional EBNA 3C fused to a modified oestrogen receptor (Maruo et al. 
2006). p16INK4a (cyclin-dependent kinase inhibitor 2A) is a tumour suppressor 
protein encoded by the CDKN2A gene (Stone et al. 1995). EBNA 3A also plays 
a role in repression of CDKN2A in LCLs established with EBNA 3A knockout 
and conditional viruses (Maruo et al. 2011, Skalska et al. 2010). The reduction 
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of BIM and p16INK4a does not involve CpG methylation, but correlated with loss 
of histone acetylation, deposition of histone H3 lysine 27 trimethylation 
(H3K27me3) and the recruitment of polycomb repressor complex 1 and 2 
(PRC1, 2) (Paschos et al. 2009, Paschos et al. 2012, McClellan et al. 2012, 
McClellan et al. 2013, Skalska et al. 2010). 
 
1.2.3.4.2 Cell cycle regulation 
The role of the EBNA 3 proteins in cell cycle regulation has been shown in Raji 
cells. An EBV positive Burkitt’s lymphoma derived cell line in which EBNA 3C is 
deleted, could be arrested in the G1 phase in the cell cycle and the cell cycle 
activity was restored by EBNA 3C expression (Allday and Farrell 1994). It has 
been shown that EBNA 3C can physically interact with many important proteins 
involved in cell cycle regulation at both G1/S and G2/M checkpoints, for 
example tumour suppressor proteins pRb and p53, oncoproteins cyclin D1 and 
Myc and DNA damage responder Chk2 and H2AX (Jha et al. 2013, Jha et al. 
2014, Saha and Robertson 2013). All these data suggest its ability to disrupt 
cell cycle control.  
 
It has been shown that NIH3T3 cells expressing EBNA 3C rescue the growth 
arrest at G1 phase caused by serum starvation and continue through G2/M 
while EBNA 3C negative cells arrest in G1 (Parker, Touitou and Allday 2000). 
The initial clue for a possible mechanism of EBNA 3C overriding G1/S 
checkpoint is the expression of EBNA 3C rescue Raji cells arrested in G1 phase 
through increasing the phosphorylation of Rb (Allday and Farrell 1994). Later 
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EBNA 3C is found to form a complex with Rb (Knight, Sharma and Robertson 
2005, Kashuba et al. 2008) and the interaction between them is stabilised in the 
presence of proteasomal inhibitor  which indicates that EBNA 3C might also 
play a role in Rb degradation apart from regulating its phosphorylation (Knight 
et al., 2005). But EBNA 3C maintains a hyperphosphorylation status of Rb but is 
not involved in its degradation in the studies using LCLs with conditionally active 
EBNC 3C (Maruo et al. 2006, Zhao et al. 2011). All these data and the earlier 
findings that EBNA 3C can increase the kinase activity of CDK6/Cyclin D1 (G1 
phase) and CDK2/Cyclin A (S phase) suggest that it disrupts G1/S checkpoint 
by regulating the phosphorylation of Rb (Knight et al. 2004, Saha et al. 2011).  
 
EBNA 3A, 3B and 3C expressing LCLs disrupt the G2/M checkpoint response 
induced by treatment with the histone deacetylase inhibitor azelaic 
bishydroxamine (ABHA) (Krauer et al. 2004). These three proteins can reduce 
the accumulation of inactive CDK1 which is inhibited by phosphorylation at 
threonine 14 and tyrosine 15 during G2/M arrest (Krauer et al. 2004). Further 
research shows that EBNA 3A and 3C can bind and inactivate Chk2 which is a 
downstream target kinase of ATM-dependent DNA damage signal pathway 
(Krauer et al. 2004, Choudhuri et al. 2007). The interaction between EBNA 3C 
and Chk2 can phosphorylate CDC25 on Serine-216 to cause its sequestration 
and degradation (Krauer et al. 2004, Choudhuri et al. 2007), so it cannot 
remove the inhibitory phosphates on CDK1 which results in G2 arrest (Matsuoka 
et al. 1998). Recent research shows that inhibition of ATM and Chk2 increases 
transformation efficiency of primary B cells and EBNA 3C is required to 
attenuate the DNA damage response induced by EBV (Nikitin et al. 2010, Li 
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and Hayward 2011). All these findings suggest a possible mechanism by which 
EBNA 3C disrupts the G2/M checkpoint to maintain the continuous proliferation 
of EBV-transformed B cells.  
 
1.2.4 EBV-associated diseases 
1.2.4.1 Infectious Mononuleosis 
During primary infection, adolescents and young adults are more likely to 
experience infectious mononucleosis (IM) than children (Krabbe, Hesse and 
Uldall 1981). IM was identified as an EBV-related disease in 1968 (Henle et al., 
1968) and symptoms can range from mild transient fever to several weeks of 
pharyngitis, lymphadenopathy (Niederman et al. 1968). It also increases the risk 
of Hodgkin’s disease but the association between the occurrence of IM and the 
risk of Hodgkin’s disease still remains uncertain (Hjalgrim et al. 2000).  
 
1.2.4.2 Lymphomas in immunocompromised patients 
Post-transplant lymphoproliferative disorders (PTLDs) is a complication in 
transplant patients who are using immunosuppressive drugs (Penn 2000) and 
70 to 100% of these disorders is associated with EBV (Juvonen et al. 2003). A 
latency III type EBV gene expression pattern was found in early PTLDs 
(Knowles 1999, Young et al. 1989, Gratama et al. 1991). The lower amount of 
EBV-specific cytotoxic T cells are not able to fight the infection and allow the B 
cells to proliferate because the immune system is suppressed in the patients by 
using immunosuppressive drugs (Holmes and Sokol 2002).  Rituximab 
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monotherapy, a monoclonal antibody directed against CD20, is a highly 
effective treatment for EBV-positive PTLD (Taylor, Marcus and Bradley 2005). 
AIDS-related lymphomas (ARLs) are mostly of B cell origin and unlike PTLDs, 
only 30 to 40% of AIDS-related BL is associated with EBV (Neri et al. 1991, 
Shibata et al. 1993).  
 
1.2.4.3 Lymphomas in immunocompetent patients 
1.2.4.3.1 Burkitt’s lymphoma (BL) 
Burkitt’s lymphoma (BL) was originally described in equatorial Africa where it is 
the commonest childhood cancer (Burkitt and O'Conor 1961). EBV is present in 
about 95% of endemic BLs in Africa but only 10%-20% in Europe and the USA 
and this difference is caused by the early age of EBV infection in Africa 
compared with industrial countries (Magrath, Jain and Bhatia 1992). In the 
endemic tumours among which Wp-restricted latency BLs are comparatively 
common, only EBNA 1 is expressed (latency I) (Rowe et al. 1986). BL is 
characterised by Myc translocation from chromosome 8 to the Ig heavy chain 
on chromosome 14 leading to the overexpression of c-myc (Zech et al. 1976). 
After translocation Myc is active and promotes cell cycle progression (Bhatia et 
al. 1993, Cesarman et al. 1987, Magrath 1990). EBV infection in latency I 
program promotes BL cell growth by inhibiting apoptosis induced by Myc 
through the upregulation of Bcl-2 and downregulation in Myc expression (Ruf et 
al. 2001).  
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In 1969 malaria was found to play a role in the generation of BL (Burkitt 1969). 
The role of malaria in BL and the mechanisms of how malaria induces the 
pathogenesis of BL are still not clear. The possible mechanisms include 
expansion of the EBV-infected B cells, suppression of EBV-specific T cell 
immunity, reactivation of EBV induced and activation-induced cytidine 
deaminase (AID)-dependent genomic translocation by malaria (reviewed by van 
Tong et al., 2017). B cell activation in malaria has been shown both 
experimentally and clinically and the risk of expansion and transition of EBV-
infected B cells enhanced by increasing proliferation of polyclonal B cells could 
lead to the emergence of a malignant B cell clone (Rochford et al., 2005). In 
malaria patients, the failure of EBV-specific T cells to control EBV-infected cells 
causes the expansion and abnormal proliferation of EBV-infected B cells 
(Whittle et al., 1984). The finding that Plasmodium falciparum infection causes 
more mature B cell lymphomas by stimulating prolonged AID expression in 
germinal centre B cells uncovers that AID is a key player for the controlling of 
chronic malaria and the lymphomagenesis induced by malaria (Robbiani et al., 
2015). 
 
1.2.4.3.2 Hodgkin’s disease (HD) 
Hodgkin’s disease is characterised by the presence of malignant 
Hodgkin/Reed-Sternberg cells (HRS) cells (Kuppers 2009) which are large, 
often multinucleated with a peculiar morphology and an unusual 
immunophenotype that is not similar to any normal cell in the body (Kuppers 
and Hansmann 2005) and some studies showed that in many cases of HD HRS 
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cells are derived from germinal centre B cells (Marafioti et al. 1997). The 
relationship of EBV and HD was established in 1989 due to the detection of 
monoclonal EBV in the HRS cells from HD (Weiss et al. 1989). EBNA 1, LMPs, 
the non-coding EBERs and miRNAs are expressed in EBV-infected HRS cells 
(Deacon et al. 1993, Niedobitek et al. 1997, Murray et al. 1992, Grasser et al. 
1994).  
 
1.2.4.4 Epithelial and other malignancies  
1.2.4.4.1 Nasopharyngeal carcinoma (NPC) 
NPC is a common malignancy in southern China (Yu and Ho et al., 1981) and 
the reports suggest that environmental factors inherent in southern Chinese are 
responsible for the high incidence of NPC in the region (Warnakulasuriya et al., 
1999; McCredie et al., 1999; Buell, 1974). Ingestion of salted fish which is a 
traditional southern Chinese food favoured by the Cantonese was suggested as 
a cause of the high incidence of NPC (Ho et al., 1978). Several nitrosamines 
have been reported in Chinese salted fish (Tannenbaum et al., 1985; Zou et al., 
1992; Zou et al., 1994). Other preserved foods, e.g. salted vegetables and 
preserved meat, were found to be related to an increase risk of NPC and like 
salted fish, these foods contain carcinogenic nitrosamines and other genotoxic 
substances (Ward et al., 2000).  
 
The EBV genome was detected in malignant epithelial cells of patients with 
NPC in 1975 (Wolf, Werner and zur Hausen 1975, Davenport and Pagano 1999) 
(Pagano et al. 1975). Compared with EBV infection in B cells, epithelial cells are 
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more difficult to infect (see section 1.2 EBV) and the EBV genome is frequently 
missing in stable cell lines established in tumours (Dittmer et al. 2008, Cheung 
et al. 1999, Lin et al. 1990). It is characterised by the abundant transcription of 
BARF1 (Brink et al. 1998, Decaussin et al. 2000, Chen et al. 1992), which is 
located in the BamHI-A fragment of EBV genome and has activity as an 
oncogene in epithelial cells (Sbih-Lammali et al. 1996, Decaussin et al. 2000, 
Wei et al. 1994).  
 
1.2.4.4.2 Gastric carcinoma 
EBV was first detected in gastric adenocarcinomas in USA in 16% of the cases 
(Shibata and Weiss 1992) and about 10% of human gastric carcinomas are 
EBV-positive (Iizasa et al. 2012). The EBV genome in EBV-associated gastric 
carcinomas is monoclonal (Imai et al. 1994) and LMP2A is expressed in about 
half of EBV-associated gastric carcinomas (Sugiura et al. 1996, Luo et al. 2005). 
The BARF1 gene is expressed in nearly 100% of EBV-associated gastric 
carcinomas so it is thought that BARF1 may play as the alternative viral 
transforming factor (zur Hausen et al. 2000). Expression of BARF1 in gastric 
carcinoma cells induces significant alterations in host gene expression, 
particularly genes related to proliferation and apoptosis and cells expressing 
BARF1 show chemoresistance and increased Bcl-2 and Bax ratio (Wang et al. 
2006).  
 
1.3 RGC-32 
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Response gene to complement-32 (RGC-32) was first identified using mRNA 
differential display PCR in primary rat oligodendrocytes (OLG) in a screen to 
find novel genes whose expression changed as a result of sub-lytic complement 
treatment with C5b-9 to mimic complement activation of the cells (Badea et al. 
1998). 32 cDNA species were identified in the screen and the cDNAs were 
designated as RGC-1 to 32 according to the order of identification (Badea et al. 
1998).  
 
The rat RGC-32 gene encodes a protein of 137 amino acids and the human 
RGC-32 gene encodes a protein of 117 amino acids (Badea et al. 1998). 
Human RGC-32 has 92% sequence similarity with rat and mouse RGC-32 
(Badea et al. 1998). RGC-32 is located at 13q14.11 and this chromosomal area 
is involved in loss of heterozygosity (LOH) or loss of copy number in glioma 
cells (Nishizaki et al. 1998, Kunwar et al. 2001). Human RGC-32 has two 
transcript variants, a shorter and a longer form (Figure 1-6). The shorter form 
lacks the end of exon 1 and the start of exon 2 (Badea et al. 2002) and the 
longer form encodes a protein with 20 more amino acids at the N terminus 
(NM_014059). Data from the West laboratory confirmed the expression of the 
shorter form in B cell lines (Schlick et al. 2011) and the longer form has not 
been detected in any cells to date.  
 
RGC-32 mRNA in rat was detected in brain, heart, kidney, lung, skin, spleen 
and thymus , but not in testis or liver (Badea et al. 1998). Human RGC-32 
mRNA expression was found in many tissues like artery, bladder, brain, breast,  
1-33 
 
 
 
 
 
 
 
 
Figure 1-6. Two RGC-32 transcript variants (modified from Schlick et al., 2011).  
Blue boxes show exons and yellow boxes show introns. Blue lines show that the end of exon 1 and the 
start of exon 2 of longer RGC-32 (C13ORF15) transcript (nm_014059) are spliced in shorter RGC-32 
transcript (AF036549). The longer form encodes a protein with an additional 20 amino acids close to the N 
terminus.  
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cervix, colon, heart, kidney, liver, lung, muscle, nerve, ovary, pancreas, skin, 
stomach, testis, thyroid (NCBI GTEx). Genotype-Tissue Expression (GTEx) 
project is a database of gene expression on RNA level in human tissues. RGC-
32 protein in human was detected in brain, heart and liver (Badea et al. 2002). 
RGC-32 mRNA expression was up-regulated in breast cancer (Kang et al. 2003, 
Fosbrink et al. 2005), colon cancer (Fosbrink et al. 2005), lung cancer (Fosbrink 
et al. 2005), ovarian cancer (Donninger et al. 2004), stomach cancer (Fosbrink 
et al. 2005), but down-regulated in multiple myeloma (Zhan et al. 2006), drug-
resistant glioblastoma (Bredel et al. 2006, Saigusa et al. 2007) and high-grade 
astrocytomas (Saigusa et al. 2007). Overexpression of RGC-32 protein level 
has been reported in several human tumours including bladder, breast, lung 
and prostate (Fosbrink et al. 2005). All these data suggest a dual role for RGC-
32 in cancer development or progression perhaps depending on the tissue type.  
 
RGC-32 (protein sequence see Figure 4-7.) has no homology with any other 
known protein and contains no motif that could suggest its biochemical function 
(Badea et al. 1998). Human RGC-32 is localised in the cytoplasm then 
translocated to the nucleus when smooth muscle cells are exposed to activated 
complement (Badea et al. 2002). Saigusa et al. have shown that RGC-32 
located in the cytoplasm of tumour cells during interphase and concentrates in 
centrosomes and spindle poles during prometaphase and metaphase (Saigusa 
et al. 2007). 
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Some evidence have been shown that RGC-32 plays a role on tumour 
promotion. Overexpression of RGC-32 in the OLG-C6 glioma cell line leads to 
an increase in DNA synthesis in response to serum growth factors (Badea et al. 
1998). Sublytic C5b-9 induces cell cycle activation and an increase in kinase 
activity of CDK1, 2 and 4 (Niculescu, Badea and Rus 1999, Rus, Niculescu and 
Shin 1996). It has been shown that RGC-32 directly binds to CDK1 and 
increases its activity by glutathione S-transferase pull-down assay in vitro and 
immunoprecipitation in vivo and western blot (Badea et al. 2002). RGC-32 was 
phosphorylated by CDK1-cyclinB1 in vitro and mutation on Thr-91 of RGC-32 
prevented the phosphorylation mediated by CDK1 (Badea et al. 2002). 
Overexpression of RGC-32 protein leads to S-phase and G2/M entry in smooth 
muscle cells (Badea et al. 2002). RGC-32 has also been suggested to influence 
muscle cell differentiation as its expression is increased to 50-fold after 24 
hours treatment in a microarray analysis of transforming growth factor (TGF)-β-
treated neural crest cells to identify downstream targets of TGF-β-induced 
smooth muscle cell differentiation (Li et al. 2007). Our group supported the role 
of RGC-32 in proliferation of EBV-infected cells by showing stable 
overexpression of it alone is enough to disrupt the G2/M checkpoint in B cell 
lines (Schlick et al. 2011). All these findings show that RGC-32 plays a role in 
the promotion of cell proliferation and cell differentiation.   
 
Other studies also suggest the role of RGC-32 as a tumour suppressor. RGC-
32 expression is frequently silenced in glioma cell lines compared with normal 
brain and restoration of RGC-32 causes the suppression of glioma cell growth 
(Saigusa et al. 2007). Overexpression of RGC-32 protein delayed mitotic 
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progression in HeLa cells (Saigusa et al. 2007). It is associated with 
centrosome/spindle poles in mitosis by immunocytochemical analysis (Saigusa 
et al. 2007) and Plk1 is also located to the central spindle in mitosis (Barr, Sillje 
and Nigg 2004). Further experiments demonstrate that RGC-32 forms a 
complex with polo-like kinase 1 (Plk1) during mitosis and is phosphorylated by 
Plk1 (Saigusa et al. 2007). This suggests that RGC-32 might negatively 
regulate the cell cycle.  
 
RGC-32 has been shown as a transcriptional target of p53 (Saigusa et al. 2007). 
It has also been identified as one of the potential downstream targets of RUNX1 
as silencing of RUNX1 mRNA expression mediated by siRNA reduced the level 
of RGC-32 markedly (Jo and Curry 2006). We found that RGC-32 protein is 
differentially upregulated in EBV-positive cell lines and RGC-32 mRNA 
expression in human B-cells is controlled by RUNX1c (Schlick et al. 2011). We 
also reported that EBNA 2 activated RUNX1 expression by binding to RUNX1 
upstream super-enhancer (Gunnell et al. 2016). RUNX1 super-enhancer 
binding by EBNA 3B and 3C attenuated the activation of RUNX1 by EBNA2 in 
BL cells (Gunnell et al. 2016). All these data show that the expression of RGC-
32 levels depend on the balance of many transcriptional factors, e.g. EBNAs, 
p53 and RUNX1.  
 
Interestingly, we found that the RGC-32 protein expression is not consistent 
with its mRNA expression in EBV-positive cell lines latency I and latency III due 
to the blocking of its translation at a post-initiation stage in latency I cells 
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(Schlick et al. 2011). It is still unclear how the changes of RGC-32 mRNA level 
by EBNAs influence the expression of its protein level.  
 
1.4 Speedy/Ringo 
RGC-32 has no homology to other human proteins, but as a CDK1 activator it 
may work similarly to Speedy/Ringo another class of CDK1 activator proteins.  
 
Speedy (xSpy) was first identified to induce rapid maturation of Xenopus 
oocytes resulting in activation of M-phase promoting factor (MPF) (Lenormand 
et al. 1999) and Xenopus Rapid INducer of G2/M progression in oocytes 
(xRINGO) was identified in an expression-cloning screen for genes involved in 
G2/M progression in Xenopus oocytes (Ferby et al. 1999). The first human 
homologue identified has 40% homology to xSpy/xRINGO and was named 
Spy1 and it was proposed to be a new cell cycle regulator which can promote 
cell proliferation by activating CDK2 at G1/S transition (Porter, Kong-Beltran and 
Donoghue 2003).  
 
xSpy/xRINGO can directly activate CDK1 and CDK2 (Karaiskou et al. 2001) 
and mammalian Speedy/RINGO family members can bind to and activate 
CDK1 and CDK2 with different efficiencies, but cannot activate CDK4 and 
CDK6 (Cheng et al. 2005a, Dinarina et al. 2005). Interestingly, the activation of 
CDK1 and CDK2 by Speedy/RINGO proteins does not require phosphorylation 
in the activation loop of the kinase domain by CAK (Karaiskou et al. 2001, 
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Cheng et al. 2005a, Cheng et al. 2005b), which is necessary for full activation of 
CDKs by cyclins. Another important difference from CDK/cyclin complexes is 
that CDK1 and CDK2 activated by xRINGO are less sensitive to inhibition by 
Myt1 which negatively regulates CDK1 activity through phosphorylation on 
residues Threonine 14 and Tyrosine 15 (Karaiskou et al. 2001).    
 
1.5 Aim of the project 
RGC-32 is upregulated in EBV-infected cells, binds CDK1 and Plk1 and plays a 
role in cell cycle regulation. RGC-32 has no homology with any other known 
proteins. This project set out to express and purify soluble milligram quantities 
of RGC-32 for functional and structural studies, investigate the interaction 
between RGC-32 and CDK1, Cyclin B1 and Plk1, examine the effect of RGC-32 
on cell cycle regulation and investigate the potential role of EBV latency III gene 
products in the regulation of RGC-32 mRNA expression.   
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2 Materials and Methods 
2.1 Reagents 
Phosphate buffer:   
                 
Buffer 
 
0.1M PO4 buffer pH7.5 
1M Na2HPO4 15ml 
1M NaH2PO4 5ml 
MilliQ H2O 180ml 
Total vol 200ml 
 
Blotting buffer: 1 litre Methanol (Fisher), 75 g Glycine (Fisher), 15 g Tris 
(hydroxymethyl)-methylamine (Fisher) and 4 litre dH2O. 
 
Buffers for His-RGC-32 purification: 
Buffer A: 40 mM PO4 buffer pH7.5, 300 mM NaCl, 2 mM Benzamidine, 2 mM 
Imidazole and 3.55 mM B-ME. 
Buffer B: 40 mM PO4 buffer pH7.5, 300 mM NaCl, 2 mM Benzamidine, 2 mM 
Imidazole, 3.55 mM B-ME and 10% NP40.  
Buffer C: 40 mM PO4 buffer pH7.5, 1 M NaCl, 2 mM Benzamidine, 2 mM 
Imidazole, 3.55 mM B-ME and 10% NP40. 
Buffer D: 40 mM PO4 buffer pH7.5, 300 mM NaCl, 2 mM Benzamidine, 2 mM 
Imidazole, 3.55 mM B-ME. 
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Buffer E: 40 mM PO4 buffer, 300 mM NaCl and 100 mM EDTA. 
Buffer F: 20 mM PO4 buffer and 200 mM NaCl. 
 
Buffer (volume/final concentration)     
X Y 
1M HEPES (KOH) pH7.5 2.5ml / 50mM 1.25ml / 50mM 
100% Glycerol 5ml / 10% 2.5ml / 10% 
200mM Benzamidine (add just before use) 500ul / 2mM 250ul / 2mM 
GuHCL (powder) 4.7765g / 1M 14.3295ul / 6M 
MilliQ H2O 42ml 21ml 
Total vol (final pH7.5) 50mls 25mls 
 
Buffers for GST-RGC-32 purification: 
Lysis buffer: 20 mM HEPES Ph7.5, 500 mM NaCl and 5 mM EDTA. 
Elution buffer (pH 7.5): 20 mM HEPES Ph7.5, 500 mM NaCl and 20 mM L-
Glutathione  
PreScission buffer: 20 mM HEPES Ph7.5, 500 mM NaCl,  
 
CsCl plasmid purification buffers: 
CsCl prep solution І: 50 mM Glucose, 25 mM Tris-HCl pH 8.0, 10 mM EDTA 
(Sigma). 
CsCl prep solution II: 200 mM NaOH, 1% SDS. 
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CsCl prep solution III: 300 ml 5 M KAC, 57.5 ML Glacial Acetic Acid, 142.5 ml 
H2O. 
CsCl-saturated butanol: 100 g Caesium Chloride (Invitrogen) in 200 ml H2O and 
200 ml butanol. 
 
The destaining buffer (kinase assay): 10% Ethanol, 5% Acetic Acid and 85% 
H2O.ECL solution: Solution I: 2.5 mM Luminol, 396 µM Coomaric Acid and 100 
mM Tris pH 8.5 in 2ml H2O. Solution II: 0.0192% Hydrogen Peroxide (H2O2) and 
100 mM Tris pH 8.5 in 2 ml H2O. Mix solution I and II before use. 
 
Fixing and staining buffer (kinase assay): 40% Methanol, 7% Acetic Acid and 
1.14 mg/ml Brilliant Blue R (Sigma-Aldrich) and 53% H2O. 
 
GSB (gel sample buffer): 50 mM Tris, 4% SDS, 5% 2-Mercaptoethanol (Sigma), 
10% glycerol, 1 mM EDTA and 0.01% Bromophenol Blue.  
 
Lysis buffer (Niculescu et al. 1997): 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 
mM MgCl2, 10 mM EDTA, 1% Nonidet P-40 (Sigma) and 0.5% (w/v) Sodium 
Deoxycholate. 
 
PBS-T: 100 PBS tablets (Fisher) and 10 ml Tween 20 (Fisher) in 10 litre dH2O. 
2.2 Cell lines 
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Akata 
Akata cell line was derived from a Japanese patient with Burkitt’s lymphoma 
and t(8;14) translocation (Takada et al., 1991). 
 
BJAB 
BJAB cell line was isolated from human Burkett’s lymphoma which is EBV 
negative, but does not have a c-myc translocation characteristic of Burkitt’s 
lymphoma cell lines.  
 
DG75 
DG75 cell line was a gift from M. Rowe and was established from a 10-year-old 
boy with EBV-negative Burkitt’s lymphoma in 1975 (Ben-Bassat et al., 1977).  
 
Mutu I  
The Mutu I cell line clone 179 was a gift from Martin Rowe (University of 
Birmingham). Mutu I cells only express EBNA1 and EBERs (Gregory, Rowe 
and Rickinson 1990) and are cultured in RPMI supplemented with 10% FBS 
and 1% PSG. Mutu I cells are passaged 1 in 5 twice per week. 
 
Mutu III 
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The Mutu III cell line clone 48 was a gift from Martin Rowe. Mutu III cells arose 
spontaneously from Mutu I cells and express all EBV genes: EBNA1, 2, 3A, 3B 
and 3C and LMP1, 2A and 2B and EBERs (Sinclair et al. 1995). 
 
Adherent cell lines 
HEK293 
HEK293 cell line was generated by transformation of human embryonic kidney 
(HEK) cells with sheared fragments of human adenovirus type 5 (Ad5) DNA 
(Davies et al., 1977).  
 
HeLa 
HeLa cell line was derived from a human cervical carcinoma from a 31 years 
old woman in 1951, which is epithelial cell line and were transformed by human 
papillomavirus 8 (Scherer et al., 1953). HeLa cells were cultured in DMEM 
supplemented 10% FBS and 1% PSG at 37°C with 5% CO2 and were 
passaged by trypsinization 1 in 10 twice weekly. 
2.3 Molecular Biology 
2.3.1 Agarose gel electrophoresis  
1 g agarose powder (Helena BioSciences) was added to 100 ml 
1×Tris/Borate/EDTA (TBE) buffer, dissolved by heating in a microwave and then 
cooled. 0.5 µl Gel Red (Biotium) was added and the agarose mixture was then 
poured into a BioRad Mini-Sub Cell GT tank (BIO-RAD) with a comb to set. The 
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comb was removed once the gel was set and the gel was submerged in 1×TBE 
then run at 90 V 400 mA for about 1 hour.   
 
2.3.2 Transformation of bacterial cells 
Around 100 ng of plasmid DNA was mixed with 100 µl of competent E.coli 
DH5α cells and incubated on ice for 45 minutes. The cells were then heat-
shocked at 42°C for 45 seconds and left on ice for 2 minutes. Transformed cells 
were spread on agar plates with appropriate antibiotics using a sterile glass 
spreader then colonies grown at 37°C overnight.  
 
2.3.3 Small-scale purification of DNA (Miniprep)  
A colony was picked using a pipette tip and grown in 2 ml LB containing 
appropriate antibiotics. The transformed bacteria were incubated at 37°C 
overnight with shaking. The overnight culture was pelleted by centrifugation at 
13,000 rpm (16,060 x g) for 1 minute using accuSpin Micro R Benchtop 
Centrifuge (Fisher). Plasmid DNA was extracted using a QIAprep Spin Miniprep 
Kit (250) (Qiagen) according to manufacturer’s instructions.  
 
2.3.4 Large-scale Caesium chloride (CsCl) DNA purification 
5 ml LB with proper antibiotics was inoculated with a single colony and grown at 
37°C during the day with shaking.The culture was transferred into 400 ml LB 
with appropriate antibodies and cultured at 37°C overnight. Cells were pelleted 
by centrifugation at 6,000 rpm (10,598 x g) for 10 minutes at 4°C using a JA-10 
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rotor in Beckman Coulter Avanti J-20 XP centrifuge. The cell pellet was 
resuspended in 14 ml solution I and then 28 ml of solution II to lyse the cells. 22 
ml solution III was then added and cell debris was pelleted by centrifugation at 
7,000 rpm (10,644 x g) for 10 minutes at 4°C using Heraeus Megafuge 8R 
centrifuge (Thermo Scientific). The supernatant was filtered through Kim wipes. 
0.6 volume of isopropanol was added and the sample was left 5-10 minutes at 
room temperature to precipitate DNA. The samples were spin down at 4,000 
rpm  (6,082 x g) for 15 minutes at 4°C using Heraeus Megafuge 8R centrifuge 
(Thermo Scientific) and then the pellets were dissolved in 6 ml MilliQ H2O and 5 
M NH4 acetate was added to precipitate the RNA.  
 
After 1 hour incubation on ice, the samples were spin down at 4,000 rpm (6082 
x g) for 10 minutes at 4°C using Heraeus Megafuge 8R centrifuge (Thermo 
Scientific) and 2 volume of 100% ethanol was added to the supernatant to 
precipitate DNA. After 10 minutes incubation at room temperature the samples 
were centrifuged at 4,000 rpm (6,082 x g) for 10 minutes at 4°C using Heraeus 
Megafuge 8R centrifuge (Thermo Scientific). Resuspended the pellets in 4 ml 
MilliQ H2O and 4.3 g CsCl and 1 mg Ethidium Bromide was added. The 
samples were removed to optiseal centrifuge tube (Beckman) and placed in Vti 
65.2 rotor. The centrifugation at 50,000 rpm (376,250 x g) overnight was used 
to separate plasmid DNA and chromosomal DNA in Beckman Optima LE-80K 
centrifuge. 
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Used a 19G needle to extract the plasmid DNA and Ethidium bromide was 
washed by adding an equal volume of CsCl saturated butanol several times. 
Dilute the DNA with 3 volume MilliQ H2O and 2 volume of ethanol. After 1 hour 
incubation at -20°C, spin down at 4,000 rpm (6,082 x g) for 20 minutes at 4°C 
using Heraeus Megafuge 8R centrifuge (Thermo Scientific) and resuspended in 
250 µl nuclease free H2O. The concentration of plasmid DNA was determined 
by spectrophotometry.  
  
2.3.5 Spectrophotometric determination of DNA concentration 
2 µl of DNA were diluted in 98 µl H2O in a UV-cuvette micro (Plastibrand) and 
measured in Eppendorf BioPhotometer at 260nm.  
 
2.3.6 Coomassie staining 
After SDS-PAGE, the gel was washed with MilliQ H2O twice for 5 minutes and 
then submerged in Bio-Safe Coomassie stain (BIO-RAD) for 1 hour on a shaker. 
The gel was washed with MilliQ H2O three times for 5 minutes and left in MilliQ 
H2O overnight at room temperature on a shaker. The gel was placed on filter 
paper and then dried using a vacuum gel dryer for 45 minutes at 80ºC.  
 
2.3.7 Immunoprecipitation 
2×107 cells were lysed in 1 ml lysis buffer (Niculescu et al. 1997) with 1 mM 
PMSF, protease inhibitor cocktail and phosphatase inhibitor cocktail and left on 
ice for 30 minutes. Samples were then sonicated at 30% amplitude for 5 × 10 
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seconds with 10 seconds intervals. The debris was removed by centrifugation 
for 5 minutes at 13,000 rpm (16,060 x g) at 4ºC using accuSpin Micro R 
Benchtop Centrifuge (Fisher). The lysates were pre-cleared with 40 µl 1:1 
Protein A-Sepharose beads slurry (Sigma-Aldrich) by incubating for 30 minutes 
at 4ºC with rotating. Then lysates were spun briefly and 2 µg of normal mouse 
IgG, anti-cyclin B1 antibody (GNS1, Santa Cruz) or anti-CDK1 antibody (cdc2 
p34, Santa Cruz) were added and the samples incubated on ice for 30 minutes. 
The immune complex was captured by adding 40 µl 1:1 Protein A-Sepharose 
beads (Sigma-Aldrich) slurry and incubated at 4ºC with rotation overnight. The 
following day, the beads were washed with 3 × 0.5 ml lysis buffer and 2 × 0.5 ml 
kinase buffer. After washing, the samples were divided into two for kinase assay 
and western blotting. 
 
2.3.8 Kinase Assay (in vivo) 
After immunoprecipitation, beads were spun down and resuspended in 5.2 µl 
mastermix including 3 µl kinase buffer, 2 µl 1 mg/ml Histone H1 and 0.2 µl 5 
µCi/µl 32P-γATP. After incubation at 37ºC for 10 minutes, samples were placed 
on ice and 20 µl 2 × GSB then added followed by western blotting.  
 
2.3.9 Kinase Assay (in vitro) 
cdk1/cdc2 Kinase Assay Kit (upstate) method: 
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2 units of recombinant CDK1/cyclin B1 (NEB) in a 1:10 dilution of Assay Dilution 
Buffer I (ADBI) (cdk1/cdc2 Kinase Assay Kit upstate) were mixed with 0.7 µM, 
1.4 µM and 2.8 µM of RGC-32 protein in elution buffer.  
 
After 10 minutes incubation at 30 ºC, 12.5 µl of 5×GSB was added and the 
samples were heated at 95ºC for 10 minutes for SDS-PAGE. After SDS-PAGE, 
the gel was fixed and stained by rocking 1 hour in fixing and staining buffer and 
then destained by rocking in destaining buffer and changing the buffer several 
times during destaining. Finally, the gel was dried onto filter paper (Whatman) 
for 45 minutes at 80 ºC. The dried gel was then exposed to a phosphor screen 
for various times depending on the intensity of the radioactivity. The phosphor 
screen was scanned by a Storm 860 scanner and analysed using ImageQuant 
5.1 software (Amersham Biosciences). 
 
In house kinase assay method: 
2 units of recombinant CDK1/cyclin B1 (NEB) in kinase buffer, 8 µg Histone H1 
(MERCK) was mixed with 0.7 µM, 1.4 µM and 2.8 µM of RGC-32 protein in 
elution buffer.   
                                                                 
2.3.10 Histidine-tagged RGC-32 preparation 
The E. coli strain BL21 pLysS was transformed with pET-16b-RGC-32 (Schlick 
et al., 2011). The bacteria were streaked out on a plate with 100 µg/ml ampicillin 
and 42 µg/ml chloramphenicol and grown overnight at 37ºC. The following day 
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50 ml LB with appropriate antibiotics was inoculated with a single colony and 
grown overnight at 37ºC. The next day 4 ml of the culture was added to each of 
5×flasks with 400 ml LB and grow at 37ºC until the OD 600 nm reached 0.5. 1 
mM IPTG was added and cells grown at 37ºC for 4 hours. The cells were then 
pelleted at 8,000 rpm (14,131 x g) at 4ºC for 15 minutes using a JA-10 rotor in 
Beckman Coulter Avanti J-20 XP centrifuge and the pellets were resuspended 
in total 80 ml cold Buffer A. To lyse the cells, the bacteria were frozen and 
thawed 3 times and then left at room temperature for 15 minutes after adding 10 
µg/ml DNase I. The cell lysates were sonicated 6×10 seconds with 10 seconds 
gaps at 25% amplitude using Vibra-Cell sonicator (SONICS) and then 
centrifuged at 9,800 rpm (22,666 x g) at 4ºC for 20 minutes using JA-20 rotor 
(Beckman) in a Beckman Coulter Avanti J-20 XP centrifuge and resuspended in 
20 ml Buffer X. This step was repeated and afterwards centrifuged at same 
condition but repsuspended in 20 ml Buffer Y.  
 
1:1 slurry of HIS-Select Nickel Affinity Gel (Sigma-Aldrich) was added into the 
supernatant and rotated for 90 minutes at 4ºC. To refold the protein, beads 
were then washed twice with 25 ml Buffer A, Buffer B, Buffer C and Buffer A. To 
elute the protein, 1 ml Buffer E was added and the beads were rotated for 20 
minutes at 4ºC. This step was repeated 5 times and the first 3 elutions pooled 
together. 40 µl of each sample of elution 1~3, 4, 5 and 6 was added 10 µl 5 × 
GSB.   
 
2.3.11 Dialysis 
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RGC-32 protein elutions 1~3 was dialysed following the instructions by Slide-A-
Lyzer Dialysis Cassettes (Thermo SCIENTIFIC) for 2 hours at 4ºC against 600 
ml Buffer F. The buffer was then changed and samples dialyzed for another 2 
hours. Following another change of buffer, samples were dialyzed overnight at 
4ºC.  
 
2.3.12 GST-tagged RGC-32 preparation  
RGC-32 was cut out of pFLAG-RGC-32 (created by Helen Webb) as a 
BamHI/NotI fragment and cloned into pGEX-6P3 digested with BamHI/NotI 
(Figure 2-1). The pGEX-6P3-RGC-32 was transformed into competent cells 
(Rosetta or Arctic cells). One colony was used to inoculate 100 ml of LB media 
containing 150 µg/ml ampicillin, which was placed in a 37°C shaker overnight. 
The next day 100 ml out of this overnight culture was used to inoculate 10 L of 
LB media (10 ml overnight culture used per 1 L) containing 150 µg/ml ampicillin 
and 30 µg/ml chloramphenicol. When the OD 600 nm reached 0.8 the flasks 
were put on ice for 45 minutes and then the cells were induced by 0.8 mM IPTG 
overnight at 18°C. The next day the cells were harvested by centrifugation at 
4,000 rpm (7,066 x g) for 20 minutes using a JA-10 rotor in Beckman Coulter 
Avanti J-20 XP centrifuge. The cell pellet was either stored at -20°C until 
required or used directly for purification. The clarified cell extract was incubated 
with 5ml of Glutathione Sepharose 4B beads (GE Healthcare), pre-washed with 
lysis buffer three times, with rotation for 4 hours at 4ºC. The beads were then 
washed twice with 35ml wash buffer (20 mM HEPES pH7.5 and 500 mM NaCl). 
The protein was eluted with 3ml of elution buffer re-adjusted pH to 7.5 (20 mM  
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Figure 2-1. Schematic graph of cloning process.  
RGC-32 was cut out of the pFLAG-RGC-32 plasmid (created by Helen Webb) as a BamHI/NotI fragment 
and cloned into pGEX-6P3 vector.  
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HEPES pH7.5, 500 mM NaCl and 20 mM L-Glutathione) then incubated at room 
temperature for 10minutes. The eluted protein was incubated with PreScission 
buffer (200μl 2mg/ml PreScission in 20 mM HEPES pH7.5, 500 mM NaCl and 1 
mM DTT) with rotation at 4°C overnight. The protein was then injected onto a 
desalting column pre-equilibrated in 20 mM HEPES pH7.5, 500 mM NaCl and 1 
mm DTT. The eluted protein was then passed through a 5ml GSTrapTM pre-
equilibrated with 20 mM HEPES pH7.5, 500 mM NaCl and 0.5 mM tris (2-
carboxyethyl) phosphine (TCEP) to remove cleaved GST. The sample was 
further purified using a gel filtration column S75 16/600 pre-equilibrated in 20 
mM HEPES pH7.5, 500 mM NaCl and 0.5 mM TCEP.  
 
2.3.13 Bradford Assay 
10 µl diluted or undiluted protein samples were added to 200 µl 1:5 dye reagent 
(BIO-RAD) and absorbance at 600 nm was measured using GloMax-Multi 
Detection System (Promega).  
 
2.3.14 SDS-PAGE 
Cell lysates in gel sample buffer (GSB) were heated at 95ºC for 10 minutes and 
vortexed. 5 µl of SeeBlue Plus2 Pre-Stained Standard marker (Invitrogen) and 
15 µl of each sample were loaded onto NuPAGE Bis-Tris gels (Invitrogen) and 
the gels were run in 1×MES or 1×MOPS NuPAGE SDS running buffer 
(Invitrogen) according to the size of proteins. Gels were electrophoresed at 
200V for 35 minutes for MES or 50 minutes for MOPS.  
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2.3.15 Western Blotting 
After SDS-PAGE, proteins were transferred to Protran Nitrocellulose Transfer 
Membrane (Whatman) in blotting buffer at 85 V for 90 minutes using a Trans-
Blot Cell (BIO-RAD). The membrane was stained in Ponceau S stain for 1 
minute, rinsed in PBS-T and then blocked with shaking in 5% milk in PBS-T for 
1 hour to prevent non-specific binding. The appropriate primary antibody diluted 
in 10 ml 5% milk in PBS-T was added to the membrane and incubated on a 
rocker overnight at 4ºC. The following day the membrane was washed with 
PBS-T three times for 10 minutes and then incubated in secondary antibody 
conjugated to horseradish peroxidise diluted in 10 ml 5% milk in PBS-T for 1 
hour on a rocker. The membrane was then washed again with PBS-T three 
times for 10 minutes. The membrane was incubated with 4 ml enhanced 
chemiluminescence (ECL) solution and then exposed to Fuji medical X-ray film 
(Fisher) for different times. The films were developed using a Konica SRX-101A 
processor.  
 
2.3.16 Pull down assay 
The pGEX-6P3, pGEX-6P3-RGC-32 and pGEX-6P3-RGC-32 T91A were 
transformed into competent cells (Rosetta cells). One colony was used to 
inoculate 100 ml of LB media containing 150 µg/ml ampicillin and 30 µg/ml 
chloramphenicol. pGEX vector has ampicillin resistance and Rosetta has pLysS 
which is a designation given to hosts carrying a chloramphenicol-resistant 
plasmid. When the OD 600 nm reached 0.8 the flasks were put on ice for 45 
minutes and then the cells were induced by 0.8 mM IPTG overnight at 18°C. 
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The next day the cells were harvested by centrifugation at 4,000 rpm (6,082 x g) 
for 20 minutes at 4°C using Heraeus Megafuge 8R centrifuge (Thermo 
Scientific). Cell pellets were dissolved in 1 ml lysis buffer (20 mM HEPES pH7.5, 
500 mM NaCl, 5 mM EDTA and 1 tablet per 50 ml proteinase inhibitor cocktail 
EDTA-free (Roche)) and sonicated at 40% amplitude 10 minutes with 10 
seconds on and 20 seconds off. The cell debris was pelleted at 13,000 rpm 
(16,060 x g) for 1 hour at 4°C using accuSpin Micro R Benchtop Centrifuge 
(Fisher) and the supernatant was incubated with 50 µl glutathione beads, pre-
washed with purification buffer three times, with rotation at 4°C overnight. 
 
2×107 BJAB or Mutu I cells were lysed in 1 ml lysis buffer (Niculescu et al. 1997) 
with 1 mM PMSF, protease inhibitor cocktail and phosphatase inhibitor cocktail 
and left on ice for 30 minutes. Samples were then sonicated at 30% amplitude 
for 5 × 10 seconds with 10 seconds intervals. The debris was removed by 
centrifugation for 5 minutes at 13,000 rpm (16,060 x g) at 4ºC using accuSpin 
Micro R Benchtop Centrifuge (Fisher). The lysates were added into the 
glutathione beads and left at room temperature for 30 minutes. The beads were 
washed with 2 × 0.5 ml lysis buffer. After washing, the samples were used for 
Western blot. 
 
2.3.17 Transient transfection (Electroporation) 
Cells were split 1 in 3 one day before electroporation . The next day cells were 
pelleted at 1,300 rpm (1,606 x g) for 10 minutes at 4ºC using accuSpin Micro R 
Benchtop Centrifuge (Fisher) and the supernatant was kept as conditioned 
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media. DNA in total maximum volume of 50 μl was incubated on ice for 10 
minutes in electroporation cuvettes (Bio-Rad). The cells were resuspended in 
serum free media to count, then pelleted and resuspended at 2 x 107 cells/ml in 
cold serum free media. 1 x 107 cells were added to each cuvette and mixed, 
then incubated on ice for 10 minutes. The samples were electroporated at 230 
V and 950 μF using a BioRad Gene Pulser II. Cells were incubated at 37 ºC for 
30 minutes then transferred to flasks containing 9 ml conditioned media. The 
samples were incubated at 37ºC for 48 hours. Cells were pelleted and 
resuspended in 10 ml PBS, then counted. Then cells were pelleted and 
resuspended in 1 ml PBS to transfer into a 1.5 ml tube. The cells were pelleted 
at 6,000 rpm (7,412 x g) for 5 minutes using accuSpin Micro R Benchtop 
Centrifuge (Fisher) and the supernatant was removed. The cell pellets were 
snap frozen on dry ice and stored at -80ºC until required. 
 
2.3.18 Transient transfection (Effectene Transfection Reagent from 
QIAGEN) 
Day before transfection, 7x105 cells were seeded in 60 mm dish in 5 ml 
appropriate growth medium containing serum and antibiotics. On the day of 
transfection (40-80% confluent), dilute 3 µg of DNA (empty & fusion) with a 
minimum concentration of 0.1µg/µl with the DNA condensation buffer EC to a 
final volume of 450 µl. After 24 µl of Enhancer was added, samples were mixed 
by vortexing for 1 second and incubated at room temperature for 2-5 minutes 
then span down for a few seconds. 75 µl Effectene Transfection reagent was 
added to the DNA-Enhancer mixture. Samples were mixed by pipetting up and 
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down 5 times, or by vortexing for 10 seconds. The samples were incubated for 
5-10 minutes at room temperature to allow transfection-complex formation. The 
growth medium was gently aspirated from the plate and cells were washed 
once with 4 ml of PBS. 4 ml fresh growth medium (complete) was added to the 
cells and 1 ml growth medium to the transfection complex. It was mixed by 
pipetting twice and added immediately drop-wise onto the cells in the dish. The 
dish was gently swirled to ensure uniform distribution of the transfection 
complexes. The cells were incubated with the transfection complexes for 18 
hours then washed with PBS and 5 ml of fresh growth medium (complete) was 
added to cells. The cells were harvested and check for protein expression by 
western blotting.  
 
2.3.19 Stable transfection 
RGC-32 was cut of pUC19 RGC-32 as an SfiI/SfiI fragment and cloned into 
pRTS-1 (gift from Georg W. Bornkamm Figure 2-2) digested by SfiI. 10 μg 
pRTS-1α RGC-32 was transfected into DG75 cells using electroporation and 
cells were incubated for 48 hours at 37ºC and 5% CO2. Cells were then counted 
and plated into 96-well plates in 100 μl at a density of 5, 50 and 500 viable cells 
per well and the spare cells were bulk cultured in flasks. Cells were cultivated in 
growth medium supplemented with 100 μM α-thioglycerol and 3 mM sodium 
pyruvate. After 5-6 days, 100 μl supplemented growth medium was added 
containing 200 μg/ml hygromycin B. After that, replace 50 μl of the cell 
supernatant with supplemented selection medium weekly.  
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Figure 2-2. pRTS-1 vector map.  
 
It has a bidirectional promoter driving expression of two genes (firefly luciferase and eGFP) and ampicillin-
resistance gene, hygromycin B resistance gene, the EBV episomal origin of replication (oriP) and the 
EBNA 1 gene.  (Bornkamm et al., 2005). Ptetbi-1 is the bidirectional tetracycline-regulated promoter. oriP 
is the EBV episomal origin of replication carrying the family of repeats (FR) and the dyad symmetry 
elements (DS). RGC-32 was cut of pUC19 RGC-32 as an SfiI/SfiI fragment and cloned into pRTS-1 
digested by SfiI.  
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2.3.20 Doxycycline treatment of stable expression of RGC-32 DG75 cells 
1 μg/ml doxycycline was added to stable expression of RGC-32 DG75 cells and 
after 48 hours, the expression of RGC-32 was verified by Western blot.  
 
2.3.21 Luciferase assay 
48 hours after transfection cells were pelleted at 1,300 rpm (1,606 x g) for 10 
minutes at 4ºC using accuSpin Micro R Benchtop Centrifuge (Fisher) and 
resuspended in 10 ml PBS and 1 ml was used as samples for Western blot 
analysis. The remaining 9 ml cells were pelleted and the cell pellet lysed in 90 µl 
passive lysis buffer (Promega) at room temperature for 30 minutes followed by 
another 30 minutes on ice. Cell debris were pelleted at 13,000 rpm (16,060 x g) 
for 5 minutes using accuSpin Micro R Benchtop Centrifuge (Fisher) and the 
supernatant was transferred to a new eppendorf. 2 x 10 µl of each lysate was 
added to a 96-well plate. 50 µl of Luciferase Assay Reagent II (LAR II) reagent 
followed by 50 µl of Stop and Glo reagent (Promega luciferase dual assay kit) 
were added to the lysates, then the signals were measured using injector Dual-
luciferase protocol of Promega. 
 
2.3.22 Etoposide treatment 
Different concentrations (depend on the cell type) of etoposide were added to 
cells and incubate at 37ºC with 5% CO2 for 8, 24 or 48 hours. The cells were 
harvested and washed. After counting in PBS, half of the cells was fixed in 1 ml 
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of 70% ethanol per 106 cells at 4ºC for at least 30 minutes then stained with 
prodidium iodide. The other half was used for protein analysis.  
 
2.3.23 Propidium Iodide staining 
After cells were washed in PBS and counted, 1 x 106 cells were transferred to a 
FACS tube and pelleted at 1,000 rpm (1,235 x g) for 5 minutes at 4ºC using 
accuSpin Micro R Benchtop Centrifuge (Fisher). Celle were fixed by suspending 
in ethanol at 1 x 106 cells/ml then washed twice in PBS. The pellet was 
resuspended in 500 µl PI stain containing 12 µl Rnase (2 mg/ml) and samples 
were incubated at room temperature for at least 30 minutes. The cell cycle 
distribution was analysed with the BD FACSCanto Flow Cytometer (BD 
Biosciences).  
 
2.3.24 Real-time Polymerase Chain Reaction 
Quantitative PCR (qPCR) was performed in duplicate using an Applied 
Biosystems 7500 real-time PCR machine. For ChIP-qPCR analysis, 3 µl DNA 
was added to a SYBR master mix containing 7.5 µl 2×GoTaq qPCR Master Mix 
(Promega), 150 µM forward and reverse primers and sterile Millipore water to a 
final volume of 15 µl. Input controls were diluted 4 fold to generate a standard 
curve for each primer set. The following conditions was used: initial 
denaturation step at 95ºC for 10 minutes, 40 cycles amplification step at 95ºC 
for 15 seconds and 60ºC for 1 minute. A dissociation curve was used by one 
cycle at 95ºC for 15 seconds, at 60ºC for 1 minute and 95ºC for 15 seconds.  
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3 Purification of RGC-32 for functional and structural 
studies 
3.1 Introduction  
RGC-32 was first identified in rat and encodes a protein of 137 amino acids. 
The human RGC-32 gene encodes a protein of 117 amino acids as a result of 
differential splice site usage and runs with a molecular weight of 15 kD on SDS-
PAGE (Badea et al. 1998, Badea et al. 2002). Human and mouse RGC-32 
share 92% homology with rat RGC-32, but human RGC-32 has no homology 
with other human proteins (Badea et al. 1998, Badea et al. 2002). Secondary 
structure prediction using JPRED (http://www.compbio.dundee.ac.uk/jpred/) 
identifies three possible α-helical regions in RGC-32 (Figure 3-1). The aim of 
this chapter was to express and purify soluble milligram quantities of RGC-32 
for functional and structural studies.  
 
3.2 Can RGC-32 increase CDK1 activity without cyclin B1? 
RGC-32 was shown to bind to the CDK1/cyclin B complex in vitro and increase 
its activity (Badea et al. 2002). This activation was dependent on 
phosphorylation of threonine 91 of RGC-32 by CDK1 (Badea et al. 2002). RGC-
32 has no homology with other proteins and there is no motif that could imply its 
function (Badea et al. 1998). However, the action of a protein (RINGO) 
described as rapid inducer of G2/M progression in Xenopus oocytes could 
indicate a possible mechanism for CDK1 activation by RGC-32. RINGO has no  
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Figure 3-1. RGC-32 secondary structure prediction using JPRED.  
RGC-32 amino acid sequence was aligned in UniRef database which combines identical sequences from 
any organism. The accession numbers link to the corresponding UniProtKB and UniParc records. Cysteine 
is highlighted as yellow, proline as blue and histidine as red. Aliphatic residues (Isoleucine, leucine and 
valine) are boxed. The three predicted α-helices in RGC-32 are shown as red cylinders under the 
sequences. 
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homology with RGC-32, but may be a functional homologue as it also binds and 
activates the kinase activity of CDK1 (Badea et al. 2002, Ferby et al. 1999). 
Interestingly, RINGO associates with CDK1 in the absence of cyclin B1 (Ferby 
et al. 1999). 
 
Experiments were therefore designed to test whether RGC-32 can increase 
CDK1 activity in the absence of cyclin B1. Previously purified recombinant His-
RGC-32 prepared via denaturation from inclusion bodies and renaturation 
would be incubated with extracts from Sf9 insect cells infected with a 
recombinant baculovirus expressing untagged human CDK1 (gift from D. 
Morgan) and the kinase activity would be determined using Histone H1 kinase 
assays based on previous protocol (Badea et al. 2002) (see figure 3-2). CAK, a 
complex of CDK7 and cyclin H, phosphorylates CDK1 and cyclin B1 complex at 
Threonine 161 in CDK1 to make it reach the full activity (Solomon et al. 1992). 
The CDK1 in extract used in this experiment was activated by insect CAK. 
Recombinant His-tagged cyclin B1 (165-433) (plasmid provided by E. Petri) 
purified from E. coli cells will be used.  
 
RGC-32 cloned in pET-16b vector was expressed in E.coli strain BL21 pLysS 
as a tagged protein with an N-terminal His tag. His-RGC-32 expression was 
induced by IPTG and purified using denaturation and renaturation techniques. 
The purity of His-RGC-32 after Nickel affinity purification was checked by SDS-
PAGE followed by Coomassie staining. The His-tagged RGC-32 protein has a 
molecular weight of 14 kD and around 3 ml His-RGC-32 (0.4 mg/ml) was  
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Figure 3-2. The strategy to study if RGC-32 can activate CDK1 activity in the absence of 
Cyclin B1. 
Recombinant RGC-32 is incubated with extract from insect cells infected with a CDK1-expressing 
recombinant baculovirs (gift from D. Morgan) and histone H1 kinase assays is carried out. Control 
experiments use soluble, active, bacterially expressed truncated Cyclin B (plasmid provided by E. Petri) to 
activate CDK1.  
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obtained from 2 L culture. His-RGC-32 was yielded with a high degree of purity 
from the pooled elutions 1~3 (0.25 mg/ml) and the concentration decreased in 
following elutions (Figure 3-3).  
 
Recombinant baculovirus carrying untagged full length CDK1 was used to infect 
Sf9 insect cells and an extract was made. Western blotting analysis confirmed 
expression of CDK1 in infected Sf9 cells. The full length CDK1 protein has a 
molecular weight of 34 kD and strongest expression was when the cells were 
infected at 0.5% and 1% (Figure 3-4).  
 
Expression of pET-28(a+) cyclin B1 (residues 165-433) was carried out in E. 
coli strain BL21 plysS. N-terminal 165 residues of Cyclin B1, which is removed 
from Cyclin B1 to improve solubility has been demonstrated natively unfolded 
(Cox et al. 2002). Cyclin B1 (165-433) containing a PEST sequence on C-
terminal and Cyclin box required for CDK1 activity and binding has been 
purified in previous experiments successfully (Petri et al. 2007). Cyclin B1 
(residues 165-433) protein has a molecular weight of around 30 kD and was 
induced as expected on incubation in the presence of IPTG (Figure 3-4). 
Different induction temperatures were used (15ºC and 37ºC) and Cyclin B1 
protein was then purified using His-select Nickel affinity beads. Compared with 
37ºC, more soluble Cyclin B1 was obtained when the induction was carried out 
at 15ºC (Figure 3-5). However, expression levels were low and not enough 
soluble protein was obtained after affinity purification (Figure 3-6).  
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Figure 3-3. SDS-PAGE gel analysis of purified His-RGC-32.  
1/375 of elution 1-3, 1/12.5 of elution 4, 5 and 6 from 2 L culture (pooled 1-3, 4, 5 and 6) of purified His-
RGC-32 protein from His-select nickel affinity resin were loaded in a SDS-PAGE gel and the gel stained 
with Coomassie stain.  
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Figure 3-4. Coomassie staining and western blot analysis of CDK1 expressionin insect 
cells.  
Sf9 insect cells were infected with different concentrations (0%, 0.1%, 0.2%, 0.5% and 1%) of baculovirus. 
Total cell lysate was separated on a Novex Bis-Tris gel (Invitrogen). A. Gel stained with Coomassie 
staining (Bio-Rad). B. Nitrocellulose membranes containing the transferred proteins were probed with 
CDK1 antibody. Bands were visualised with ECL. 
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Figure 3-5. Western blotting analysis of cyclin B1 expression and solubilisation.  
Temperature of 15°C and 37°C expression from 50 ml culture was carried out at prior to extraction in 
buffer contained 20mM Ph8.3 Tris, 0.8M NaCl and 10% glycerol. 1/400 of pellet and 1/400 of supernatant 
were separated using an SDA-PAGE gel. 
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Figure 3-6. Coomassie staining analysis of cyclin B1 purification. 
Temperature of 20°C and 25°C expression from 1 L culture was carried out at prior to extraction in buffer 
contained 20mM pH 8.3 Tris, 0.8M NaCl and 10% glycerol. 1/25000 of pellet and 1/25000 of supernatant 
were separated using an SDA-PAGE gel. The gel stained with Coomassie stain.  
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3.3 The effect of RGC-32 on CDK1 kinase activity 
RGC-32 was shown to pull down the CDK1/Cyclin B1 complex in vitro and 
immunoprecipitate CDK1 in vitro and increase the activity of CDK1 in a manner 
dependent on the phosphorylation of threonine 91 on RGC-32 by CDK1 (Badea 
et al. 2002). Other evidence showed that transiently overexpressed Flag- or 
Myc-RGC-32 did not co-precipitate with exogenously expressed Cyclin B1 in 
HEK 293-T cells (Saigusa et al. 2007). Previously in the West lab, purified 
recombinant His-RGC-32 was observed to increase the activity of CDK1 in vitro 
by Histone H1 kinase assay measuring the phosphorylation of Histone H1 by 
CDK1 using 32P-labelled ATP (Schlick et al. 2011). Purity of RGC-32 purified 
was assessed as good enough to test whether His-RGC-32 was functional 
using kinase assays. To check if the purified His-RGC-32 generated was active, 
in vitro kinase assays were carried out. CDK1 activity increased more than 4-
fold at the highest His-RGC-32 protein concentration (1.4 µM) (Figure 3-7) 
indicating that the purified His-RGC-32 was active.  
 
To investigate the mechanism of the activation of CDK1 by RGC-32, we 
collaborated with Jane Endicott and Nick Brown (initially University of Oxford, 
now University of Newcastle). To determine whether the activation of CDK1 by 
RGC-32 was dependent on CAK phosphorylation of CDK1 and whether RGC-
32 can activate other CDKs such as CDK2, in vitro kinase assays were carried 
out. Purified recombinant dialysed and undialysed His-RGC-32 protein was 
used. Purified CDK1 and CDK complexes in activated (pCDK1/Cyclin B and 
pCDK2/Cyclin A) and unactivated (CDK1/Cyclin B) forms provided as part of  
3-70 
 
 
 
 
 
Figure 3-7. The effect of His-RGC-32 on CDK1 kinase activity.  
Recombinant CDK1/cyclin B1 (NEB) was mixed with His-RGC-32 to a final concentration of 0.7 and 1.4 
µM in the presence of γ-32P ATP and histone H1 as substrate. A. Samples were separated using a 10% 
NuPAGE Novex Bis-Tris gel (Invitrogen). B. Radioactively phosphorylated histone H1 was measured using 
a phosphorimager. CDK1 activity was quantified and expressed relative to the control (no RGC-32) (n=1). 
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collaboration with University of Oxford (Figure 3-8). Initially, whether RGC-32 
can activate pCDK1/Cyclin B, pCDK2/Cyclin A or CDK1/Cyclin B was examined. 
Whether RGC-32 can activate CDK1 without CAK (CDK7/Cyclin H) 
phosphorylation was also examined. 
 
Two-thirds of the purified His-RGC-32 from 2 L culture was dialysed in dialysis 
buffer (20 mM PO4 buffer and 200 mM NaCl) and undialysed protein was 
retained in elution buffer (40 mM PO4 buffer, 300 mM NaCl and 100 mM EDTA). 
Unfortunately, the experiments carried out by Nick Brown in University of Oxford 
failed to show RGC-32 activation of any of the kinases (pCDK1/Cyclin B, 
pCDK2/cyclin A and CDK1/Cyclin B) (Figure 3-8). Kinase activity was measured 
by quantifying the phosphorylation of Histone H1 by kinases using 32P-labelled 
ATP and there was no increase in the levels of phospho-Histone H1 compared 
in the presence of RGC-32. Undialysed RGC-32 inhibited the activity of any 
kinases as no radioactive activity was detected in experiments containing 
undialysed RGC-32 (lane 3, 6, 9, 12 and 15). This was because the undialysed 
His-RGC-32 used was eluted in 40 mM PO4, 300 mM NaCl and 100 mM EDTA. 
Mg2+ is required for kinase activity was therefore likely to be chelated by EDTA. 
Although some dialysed His-RGC-32 in 20 mM PO4 buffer pH 7.5 was also 
used, it was too dilute (RGC-32:CDK1 14 ng: 1 ng) in the experiment done in 
University of Oxford compared to our experiment (RGC-32:CDK1 500 ng: 1 ng), 
in which CDK1 activity increased more than 4-fold at the highest His-RGC-32 
protein concentration (Figure 3-7). The dialysed RGC-32 produced for these 
experiments was therefore at too low concentration.  
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Figure 3-8. The effect of His-RGC-32 on different CDK/cyclin complexes.  
Recombinant kinases or kinase complexes were mixed with dialysed and un-dialysed His-RGC-32 in the 
presence of γ-32P ATP and histone H1 and samples were separated in a 12.5% SDS-PAGE gel. 
Experiment carried out by Nick Brown (initially University of Oxford, now University of Newcastle). A. 
Analysis of the CDK1 and CDK2 complexes. B. Analysis of the CDK7/Cyclin H complex.  
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To determine whether adding an excess of magnesium cations could improve 
the kinase assay results with the undialysed protein, Mg2+ was added to the 
reaction to a final concentration of 35 mM. 35 mM Mg2+ was higher than the 
concentration of EDTA (10 mM) in the purified His-RGC-32 protein preparation. 
The results showed that the activity of CDK1/Cylin B was increased by 2-fold 
using 1 ng Oxford-purifed CDK1 (Figure 3-9C), and 2.5-fold using 2 ng Oxford-
purified CDK1 (Figure 3-10 C) with the highest His-RGC-32 protein 
concentration used (2.8 µM). This is lower than previously demonstrated in our 
lab which showed that CDK1 activity was enhanced by up to 12-fold with 5 µM 
RGC-32 protein (Schlick et al., 2011). We therefore examined the quality of the 
RGC-32 protein. 
 
3.4 Examination of His-RGC-32 aggregation 
Dynamic Light Scattering (DLS), a technique to measure the size and 
distribution of proteins, was carried out to investigate whether there was any 
protein aggregation in the His-RGC-32 we purified (Figure 3-11). It showed that 
all His-RGC-32 preparations were homogenous but both the undialysed and 
dialysed samples contained a lot of aggregation (Figure 3-11). The dialysed 
sample (Figure 3-11B) was centrifuged to pellet aggregates and the remaining 
soluble RGC-32 (Figure 3-11C) had a smaller volume in DLS, consistent with 
the lack of aggregates. 
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Figure 3-9. The effect of His-RGC-32 CDK1 kinase activity in CDK1/cyclin B1 preparations.  
1ng recombinant CDK1/Cyclin B1 (NEB) or pCDK1/cyclin B1 (Oxford) was mixed with His-RGC-32 to a 
final concentration of 0.7, 1.4 and 2.8 µM in the presence of γ-32P ATP and histone H1. The concentration 
of Mg2+ was 35 mM (n=1). A. SDS-PAGE analysis of histone H1 phosphorylatioin using 1 ng recombinant 
CDK1/cyclin B1 (NEB) or pCDK1/cyclin B1 (Oxford). B & C. CDK1 activity in A was quantified. 
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Figure 3-10. The effect of His-RGC-32 CDK1 kinase activity in CDK1/cyclin B1 
preparations.  
Recombinant CDK1/Cyclin B1 (NEB) or pCDK1/cyclin B1 (Oxford) was mixed with His-RGC-32 to a final 
concentration of 0.7, 1.4 and 2.8 µM in the presence of γ-32P ATP and histone H1. The concentration of 
Mg2+ was 35 mM (n=1). A. SDS-PAGE analysis of histone H1 phosphorylatioin using 2 ng recombinant 
CDK1/cyclin B1 (NEB) or pCDK1/cyclin B1 (Oxford). B & C. CDK1 activity in A was quantified.   
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Figure 3-11. Analysis of His-tagged RGC-32 using Dynamic Light Scattering.  
Three measurements are shown as different colors. A. Un-dialysed His-tagged RGC-32. B. Dialysed His-
tagged RGC-32. C. Supernatant from B after centrifugation. Larger volume indicates aggregates. 
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3.5 Expression of GST-RGC-32 
To improve solubility, RGC-32 was re-cloned as a Glutathione-S-Transferase 
(GST) fusion protein using the pGEX-6P3 vector, since GST often improves the 
solubility of proteins. Expression and solubilisation of GST-RGC-32 was 
compared to His-RGC-32 using RosettaTM 2(DE3) pLysS SinglesTM competent 
cells (Novagen) and Arctic Express (DE3) competent cells (Agilent 
Technologies) and different extraction buffers. Rosetta 2 cells are BL21 
derivatives designed to enhance the expression of eukaryotic proteins that 
contain codons rarely used in E. coli (Novagen). Arctic cells are derived from 
BL21 competent cells and co-express chaperonins Cpn10 and 60 from the 
psychrophilic bacterium, Oleispira Antarctica (Agilent Technologies) which show 
high protein refolding activities at temperatures of 4 to 12ºC (Ferrer et al. 2003).  
 
RGC-32 fusion protein expression was induced by addition of 0.8 mM IPTG at 
12°C and 18°C respectively for Arctic and Rosetta cells. Cell pellets were 
resuspended in different buffers in the presence of protease inhibitors and 5 
mM EDTA. Buffer A contained 20 mM HEPES pH7.5 and 500 mM NaCl. Buffer 
B contained 20 mM HEPES pH7.5 and 200 mM NaCl. Buffer C contained 20 
mM HEPES pH7.5, 200 mM NaCl and 10% glycerol. Buffer D contained 20 mM 
HEPES pH7.5, 200 mM NaCl and 1% Tween 20. The supernatant and pellet 
after lysis of Arctic (Figure 3-12) or Rosetta (Figure 3-13) cells were loaded on a 
gel.  
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Figure 3-12. His-tagged RGC-32 and GST-tagged RGC-32 purification test in Arctic cells.  
A. Stained SDS-PAGE gel of supernatant from lysates of Arctic cells induced to express His-RGC-32 or 
GST-RGC-32. Cells were lysed in different buffers (A-D) and 1/60 of soluble supernatant as analysed.  B. 
Stained SDS-PAGE gel 1/60 cell pellets from lysates of Arctic cells. The His-RGC-32 protein has a 
molecular weight of 17 kD and GST-RGC-32 protein has a molecular weight of 40 kD. 
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Figure 3-13. His-tagged and GST-tagged RGC-32 purification test in Rosetta cells.  
A. Stained SDS-PAGE gel of supernatant from lysates of Rosetta cells induced to express His-RGC-32 or 
GST-RGC-32. Cells were lysed in different buffers (A-D) and 1/60 of soluble supernatant were analysed.  
B. Glutathione or His beads were added to the supernatant and protein purified on beads was loaded on a 
gel.   
 
 
 
3-80 
 
For Arctic cells, more soluble GST-RGC-32 was detected when using lysis 
buffer A and for His-RGC-32 buffer B and C are better than buffer A and D for 
solubility (Figure 3-12A). GST was self-cleaved in each buffer (Figure 3-12A). 
Also insoluble GST-RGC-32 and His-RGC-32 were detected in pellet when 
using all lysis buffers (Figure 3-12B). 
 
For Rosetta cells, less soluble His-RGC-32 protein was obtained compared with 
GST-RGC-32 protein in the supernatant (Figure 3-13A). More GST-RGC-32 
could be detected when lysed in buffer A than other buffers and GST was again 
self-cleaved in each buffer (Figure 3-13A). Glutathione or His beads was added 
to the supernatant and protein purified on beads were loaded on the gel. GST-
RGC32 protein was purified effectively (Figure 3-13B).  
 
To summarise, in the purification test of GST-RGC-32 in Rosetta or Arctic cells, 
more soluble RGC-32 was obtained using Rosetta cells rather than Arctic cells 
and more RGC-32 protein was obtained when using buffer A. For further 
experiments GST-RGC-32 was expressed using Rosetta cells and buffer A. 
GST-RGC-32 was more soluble so used this from now on. Further experiments 
with GST-RGC-32 are described in Chapter 4. Since we had optimised GST-
RGC-32 purification we attempted to obtain sufficient purified soluble RGC-32 
for structural studies. 
 
3.6 Large scale GST-RGC-32 purification using Rosetta cells 
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3L of Rosetta cells expressing pGEX-6P3 RGC-32 were induced by IPTG to 
express GST-RGC-32 protein and lysates prepared using buffer A. The RGC-
32 on beads was eluted with elution buffer contained 20 mM HEPES pH 7.5, 
500 mM NaCl and 20 mM L-Glutathione. Then the eluted protein was incubated 
with the PreScission protease (200 µl 2 mg/ml PreScission in 20 mM HEPES 
pH7.5, 500 mM NaCl and 1 mM DTT) to cleave the GST tag. Samples of elution 
and GST tag cleaved off were loaded on a gel (Figure 3-14A). The GST protein 
is visible as a 26 kD protein and RGC-32 as a 14 kD protein. The GST tag was 
successfully cleaved from GST-RGC-32 protein. To verify that the cleaved 
product was RGC-32, samples were analysed using an anti-RGC-32 antibody 
by Western blotting (Figure 3-14B). Different sizes of proteins (61, 44, 32, 15 
and 12 kD) were detected. The detected proteins were RGC-32 plus additional 
larger proteins that could be dimers or trimers. There were also some smaller 
species that may be cleavage products. Purified RGC-32 was concentrated to 
0.9 mg/ml in a total volume of 100 µl.  
 
This experiment demonstrated that we were able to purify soluble RGC-32 for 
crystal trials to offer more structural information of RGC-32, so we next scaled-
up the preparation to obtain milligram quantities. Also, we needed to examine 
the interaction between RGC-32 and CDK1 using GST-RGC-32 we made to 
carry on the collaboration with Professor Jane Endicott and Dr. Nick Brown 
(University of Newcastle) (see Chapter 4).  
 
To obtain mg amounts of RGC-32 for crystalisation, GST-RGC-32 was purified 
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Figure 3-14. GST-RGC-32 purification from 3L Rosetta culture.  
A. GST-RGC-32 elution before and after precission treatment. B. Purified cleaved RGC-32 analysed by 
western blotting using polyclonal anti-RGC-32 antibody 
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from 10 L of Rosetta cells. GST-RGC-32 was eluted and the GST tag cleaved 
off using the PreScission protease (Figure 3-15). A HiTrap desalting column (GE 
Healthcare Life Sciences) was then used to remove free glutathione and a 
GSTrap 4B column (GE Healthcare Life Sciences) was used to remove GST 
from cleaved RGC-32. GST was completely removed after running through a 
GSTrap column (Figure 3-16).   
 
RGC-32 protein was concentrated and applied to a gel filtration column S75 
16/60 to further purify the sample. Fraction C10 to D1 was confirmed as 
containing RGC-32 protein (Figure 3-17A) by SDS-PAGE analysis (Figure 3-
17B). It has a very low absorbance because of no tryptophan residues in RGC-
32. The high molecular weight contaminants (first peak from gel filtration in 
Figure 3-17A) were successfully removed after gel filtration (Figure 3-17B). The 
purified RGC-32 was concentrated to 1.5 mg/ml in a total volume of 170 µl.  
 
 
3.7 Crystallisation trials 
Crystallization screening was performed with RGC-32 at a concentration of 1.5 
mg/ml using Crystal Phoenix (Art Robbins Instruments) employing the sitting 
drop vapour diffusion method. Commercial screening kits used were Structure 
Screen 1+2 (Molecular Dimensions), PEG/Ion HT (Hampton Research), Natrix 
HT (Hampton Research), Index HT (Hampton Research), SaltRx HT (Hampton 
Research) and JCSG-plus (Molecular Dimensions).  
 
Structure Screen 1 & 2 is a 96 reagent, sparse-matrix screen for Structure  
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Figure 3-15. GST-RGC-32 purification from 10L Rosetta culture.  
GST-RGC-32 elution before and after precission treatment.  
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Figure 3-16. GST-RGC-32 purification from 10L Rosetta culture.  
RGC-32 after precission treatment (5, 10 and 15 µl) and after passing through a Glutathione column to 
remove GST protein from sample. 
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Figure 3-17. Gel filtration purification of RGC-32.  
(A) RGC-32 was concentrated and applied to an S75 16/60 gel filtration column pre-equilibrated in 10 mM 
HEPES pH7.5, 500 mM NaCl and 0.5 mM TCEP. 1.7 ml fractions were collected. (B) Samples (fraction 
1B11 to 1C5 from first peak and fraction C10 to D1 from second peak) after gel filtration were analysed by 
SDS-PAGE and gel staining. 
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Screen 1 and the classic extension to this screen Structure Screen 2 (Jancarik 
and Kim, 1991). PEG/Ion HT combines PEG/Ion and PEG/Ion 2 in a single 96 
deep well block. PEG/Ion is a sparse matrix profile of anions and cations in the 
presence of monodisperse polyethylene glycol (PEG) 3,350 over pH 4.5 – 9.2 
and PEG/Ion 2 is a profile of titrated organic acids in the presence of 
monodisperse PEG 3,350 over pH levels 3.7 – 8.8 
(http://hamptonresearch.com/product_detail.aspx?sid=30&pid=11). Natrix HT 
contains 1 ml of each reagent from Natrix and Natrix 2 
(https://hamptonresearch.com/product_detail.aspx?cid=1&sid=27&pid=8). 
Natrix contains 48 unique reagents, 10 ml each and is based on the sparse 
matrix formulation (Scott et al., 1995). As an extension of Natrix, Natrix 2 
contains 48 unique reagents, 10 ml each and based on extracting patterns from 
crystallization data as well as reagent formulations (Berger et al., 1996). Index 
HT contains 10 ml 96 unique reagents in a single deep well block format 
(http://hamptonresearch.com/product_detail.aspx?sid=24&pid=5). SaltRx HT 
contains the 96 reagents from SaltRx 1 and SaltRx 2 in a single deep well block 
format. SaltRx 1 and SaltRx 2 contain 10 ml unique reagents 1-48 and 49-96 of 
the original SaltRx 96 reagent kit 
(http://hamptonresearch.com/product_detail.aspx?sid=32&pid=12). JCSG-plus 
contains 10 ml each of 96 sterile filtered reagents incorporating PEG, salts, 
neutralised organic acids or organic precipitants across a pH range from 4.0 to 
10.5, and including a range of salt additives (Newman et al., 2005). 
 
Plates were kept at 20°C to allow the crystals grow. Unfortunately no crystal hits 
were obtained. To increase the concentration of RGC-32 obtained from  
3-88 
 
 
 
 
 
 
 
Figure 3-18. Purified RGC-32 from 20 L cell culture.  
Samples of RGC-32 after concentration (10 µl and 3 µl) and before concentration were analysed by SDS-
PAGE and gel staining. 
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purification, 20 L Rosetta cells expressing pGEX-6P3 RGC-32 were cultured 
and protein purified to higher concentration up to 4.5 mg/ml for 200 µl (Figure 3-
18). Again the sitting drop vapour diffusion technique was employed with the 
commercial screening kits Structure Screen 1+2 (Molecular Dimensions), Natrix 
HT (Hampton Research), Index HT (Hampton Research), SaltRx HT (Hampton 
Research) and JCSG-plus (Molecular Dimensions) at 4 and 20°C. No crystal 
hits were obtained at either temperature. 
 
3.8 Discussion 
RGC-32 can bind to CDK1/Cyclin B1 complex in vitro (Badea et al. 2002), but 
other evidence shows that transiently overexpressed Flag- or Myc-RGC-32 did 
not co-precipitate with exogenously expressed Cyclin B1 in HEK 293-T cells 
(Saigusa et al. 2007). It implies a possibility of RGC-32 competing with Cyclin 
B1 for CDK1. RGC-32 has been shown to increase CDK1 activity in a manner 
dependent on the phosphorylation of threonine 91 in RGC-32 by CDK1 (Badea 
et al. 2002). Kinase assays using recombinant RGC-32 protein confirmed this 
increase of CDK1 activity. Like RGC-32, xRINGO/Speedy has been shown to 
activate CDK1 but does not associate with CDK1/Cyclin B complexes (Gastwirt, 
McAndrew and Donoghue 2007). Further evidence confirms that xRINGO can 
bind CDK1 and Cyclin B individually but not the CDK1/Cyclin B complex (Ferby 
et al. 1999). More interestingly Speedy/RINGO could even bypass the 
requirement for phosphorylation in the activation loop of CDKs (Karaiskou et al. 
2001). Like the ability of RGC-32 disrupting the cell cycle, overexpression of 
Speedy/RINGO was shown to reduce the percentage of cells in G1 phase of the  
cell cycle, promoted late S phase progression and disrupted the G2/M 
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checkpoint (Porter et al. 2002, Cheng and Solomon 2008). It would be 
interesting to see if RGC-32 works at similar way to Speedy/RINGO. Previously 
experiments were designed to test whether RGC-32 can increase CDK1 activity 
in the absence of cyclin B1 (Figure 3-2). The initial experiments designed to 
determine whether RGC-32 can increase CDK1 activity without Cyclin B1 were 
not conclusive because we could not purify enough soluble Cyclin B1. So we 
changed the strategy of the experiments to use the CDK1 and Cyclin B1 
provided as part of collaboration with Professor Jane Endicott and Dr. Nick 
Brown (initially University of Oxford, now University of Newcastle). 
 
Previously in the West lab, RGC-32 was purified as a His-tagged protein from 
inclusion bodies using denaturation and renaturation. To improve the solubility 
of RGC-32 protein, we successfully cloned RGC-32 DNA into pGEX-6P3 vector 
and expressed it in Rosetta and Arctic cells. In the purification test, the results 
showed that the solubility of RGC-32 is better with a GST tag than His tag and 
in Rosetta cells than Arctic cells. Therefore RGC-32 was purified using a 
glutathione column and gel filtration and 4.5 mg/ml for 200 µl (900 µg in total) 
was achieved from 20 L cells. Unfortunately no crystal has been yielded to date. 
Further crystallisation trials could be made with higher concentration of RGC-32 
or the temperature for setting up the crystal trials. Another attempt is to co-
crystallise RGC-32 with one of its interaction partner to yield diffraction quality 
crystals, e.g. CDK1 becausae the complex formed could be more soluble and 
stable compared with single protein.   
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Next, it is important to determine whether there is an interaction between RGC-
32 and CDK1, or Cyclin B1, or Plk1 in B cells. It can be achieved by pull-down 
assays using GST-RGC-32 (see Chapter 4). The interaction of RGC-32 and 
CDK1 or Cyclin B1 in vitro could also be tested using surface plasmon 
resonance (SPR) which is an optical technique used for detecting two different 
molecules in which one is mobile (analyte) and one is fixed on a thin film (ligand) 
(Schuck 1997). Binding of the analyte to ligand changes the refractive index of 
the film and the angle of extinction of light reflected after polarised light 
impinges on the film is changed and measured in reflected intensity (Drescher, 
Ramakrishnan and Drescher 2009). Firstly, RGC-32 will be immobilised by an 
amine-coupling reaction on a senor chip (Biacore) which is inserted into the flow 
chamber. Then CDK1 or CDK1/Cyclin B1 complex will flow through the chip 
fixed with RGC-32 to produce a small change in refractive index at the gold 
surface which can be quantified, so binding affinities can be yielded from the 
ratio of rate constants to obtain a characterisation of RGC-32 and CDK1 or 
CDK1/Cyclin B1 interaction. 
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4 Mechanism of RGC-32 disrupting cell cycle 
4.1 Introduction 
RGC-32 has been shown to bind CDK1/Cyclin B1 complex in vitro and in vivo 
(Badea et al. 2002). This interaction appears to be specific since RGC-32 does 
not bind CDK2 or CDK4 (Badea et al. 2002). RGC-32 activates CDK1 kinase 
activity and both binding and the enhancement of CDK1 activity appear to 
depend on the phosphorylation of RGC-32 by CDK1 at Threonine 91 (Badea et 
al. 2002). Our lab confirmed that RGC-32 activates CDK1/Cyclin B1 in vitro 
(Schlick et al. 2011), but the mechanism of CDK1 activation by RGC-32 
remains unclear. Others have reported that RGC-32 can associate with the 
centrosome-associated polo-like kinase 1 (Plk1) in human embryonic kidney 
(HEK) 293-T cells and can be phosphorylated by Plk1 in vitro (Saigusa et al. 
2007). These authors also stated that they were unable to co-precipitate Cyclin 
B1 with RGC-32 (Saigusa et al. 2007). Initial attempts to address whether RGC-
32 activates CDK1 in the absence of Cyclin B1 in Chapter 3 were not 
conclusive so we next investigated the interaction between RGC-32 and CDK1 
and Cyclin B1 and Plk1 using pull-down assays. 
 
The role for RGC-32 in the promotion of cell proliferation was demonstrated in 
oligodendrocytes (OLG) (Badea et al. 1998) and G1 arrested smooth muscle 
cells (Badea et al. 2002). Our group showed that overexpression of RGC-32 
alone can disrupt the G2/M checkpoint (Schlick et al. 2011). Interestingly, other 
studies have revealed the role of RGC-32 as a tumour suppressor as it was 
found to be absent in glioma cell lines and restoration of it caused suppression 
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of cell growth (Saigusa et al. 2007). In this chapter, we set out to further 
examine the effect of RGC-32 on cell cycle regulation by generating stable cell-
lines containing inducible RGC-32 expression constructs. 
 
4.2 RGC-32 can interact with CDK1 and Plk1 but not Cyclin B 
To verify the association of RGC-32 with CDK1 and Plk1, GST pull-down 
assays were carried out using GST-tagged RGC-32 incubated with lysates from 
the EBV negative B cell lymphoma cell line BJAB. We found that GST-tagged 
RGC-32 was able to pull down CDK1 and Plk1. This interaction was specific 
because beads alone or GST alone did not pull down RGC-32 (Figure 4-1). It 
has been shown that the Threonine 91 is the phosphorylation site of RGC-32 by 
CDK1 and important for RGC-32 increasing CDK1 kinase activity (Badea et al. 
2002). So we also tested if RGC-32 with a threonine 91 to alanine substitution 
(T91A) could influence the interaction of RGC-32 and CDK1 or Plk1. Our results 
showed that GST-tagged RGC-32 mutant T91A could also pull down CDK1 and 
Plk1 (Figure 4-1). The interaction of RGC-32 with CDK1 appears to be specific 
because we showed that GST-tagged RGC-32 failed to pull down CDK2 (Figure 
4-1) which is consistent with previous reports (Badea et al. 2002). Saigusa et al. 
stated that they could not demonstrate a physical interaction between RGC-32 
and Cyclin B1 (Saigusa et al. 2007). Our results showed that GST-tagged RGC-
32 did not pull down Cyclin B1 (Figure 4-1) which strengthen the evidence that 
Cyclin B1 is not in the complex of CDK1 and RGC-32. The pull-down assays in 
another Burkitt’s lymphoma cell line Mutu I showed similar results that GST-
tagged RGC-32 could pull down CDK1, but not CDK2 and Cyclin B1 and that  
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Figure 4-1. Western blot analysis of in vitro interaction of RGC-32 in BJAB cells. 
Glutathione agarose beads or beads bound to GST, GST-RGC-32 (WT) or GST-RGC32 mutant (T91A) 
were mixed with BJAB total cell lysates. CDK2 was used as a negative control.  
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this interaction of RGC-32 with CDK1 is not dependent on Threonine 91 of 
RGC-32 (Figure 4-2). 
 
4.3 Mapping the regions of interaction between RGC-32 and 
CDK1 or Plk1 
To identify the regions of RGC-32 required for the interaction with CDK1 and 
Plk1 we generated deletion mutants of RGC-32. To help in the design of 
mutants we used JPred to predict RGC-32 secondary structure (Figure 3-1). 
The protein sequence was searched against UniRef 90 to identify regions of α-
helix, β-strand and coil. Three predicted α-helices (5-23 aa, 31-43 aa and 101-
115 aa) predicted were identified (Figure 3-1). Next, to localize the region of 
RGC-32 that directly interacts with CDK1 or Plk1, we generated four GST-
tagged truncation mutants designed to delete each of the predicted helices 
sequentially (Figure 4-3). Truncation 1-25, spanning amino acid residues 1-25, 
contains one potential α-helices; truncation 1-50, spanning amino acid residues 
1-50, contains two potential α-helices; truncation 1-75 or 1-100, spanning amino 
acid residues 1-75 or 1-100, contains two potential α-helices and following 25 or 
50 residues. Mutants were expressed and purified on Glutathione beads and 
used in GST pull-down assays to identify regions required for the interaction of 
RGC-32 with CDK1 or Plk1. 
 
In two independent experiments (Figure 4-4), truncation 1-75 and 1-100 pulled 
down CDK1, but truncations 1-25 and 1-50 did not. This indicates that 50-75 
residues of RGC-32 are crucial for CDK1 binding (Figure 4-6). 
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Figure 4-2. Western blot analysis of in vitro interaction of RGC-32 in Mutu I cells. 
Glutathione agarose beads or beads bound to GST, GST-RGC-32 (WT) or GST-RGC32 mutant (T91A) 
were mixed with Mutu I total cell lysates. CDK2 was used as a negative control 
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Figure 4-3. Schematic diagram of RGC-32 truncations.   
RGC-32 was shown as blue bars and three predicted helical regions in RGC-32 were shown as red bars.   
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Figure 4-4. In vitro interaction of RGC-32 truncations with CDK1. 
Glutathione agarose beads or beads bound to GST, GST-RGC-32 FL or truncations were mixed with 
BJAB total cell lysates. A and C. SDS-PAGE gel analysis of GST, GST-RGC-32 FL and truncations used 
in pull-down assay. B and D. Western blot analysis of interaction of RGC-32 truncations with CDK1.  
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Figure 4-5. In vitro interaction of RGC-32 truncations with Plk1. 
Glutathione agarose beads or beads bound to GST, GST-RGC-32 FL or truncations were mixed with 
BJAB total cell lysates. A and C. SDS-PAGE gel analysis of GST, GST-RGC-32 FL and truncations used 
in pull-down assay. B and D. Western blot analysis of interaction of RGC-32 truncations with Plk1.  
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Figure 4-6. Summary of potential RGC32 binding domains with CDK1 and Plk1. 
RGC-32 was shown as blue bars and three predicted helical regions in RGC-32 were shown as red bars.   ̶ 
means there is no binding between RGC-32 truncations and CDK1 or Plk1 and + means there is binding.  
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For Plk1 binding (Figure 4-5), only truncation 1-25 failed to pull down Plk1. All 
other truncations (1-50, 1-75 and 1-100) and full length RGC-32 pulled down 
Plk1 successfully. Hence amino acid residues between 25 and 50 in the RGC-
32 are required for Plk1 binding (Figure 4-6). 
 
4.4 Mutation analysis of RGC-32 binding to CDK1 or Plk1 
To further identify the functional binding sites of RGC-32, we aligned RGC-32 in 
difference species to identify amino acids within the regions identified as 
important for CDK1 or Plk1 binding that are conserved (NCBI) (Figure 4-7). We 
then identified conserved amino acids that may play a role in protein-protein 
interactions to mutate (amino acid framed in black boxes in Figure 4-8). To 
study CDK1 binding, we mutated the hydrophobic amino acids phenylalanine 68 
and 70 to alanine (Figure 4-8). To study PLK1 binding, we mutated the 
hydrophobic amino acids tyrosine 33 to A and positively-charged cluster lysine 
41, arginine 42 and 43 to negatively charged glutamic acid (Figure 4-8).  
 
The results of two independent experiments showed that substituting both 
phenylalanine to alanine in RGC-32 increased the binding activity for CDK1 to 
1.8-fold compared to RGC-32 wildtype (Figure 4-9E). But this change was not 
significant using statistical analysis so it indicated the interaction of RGC-32 and 
CDK1 was not dependent on F68 and 70 on RGC-32.  
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Figure 4-7. Conserved domains alignment of RGC-32 in different species. 
The alignment was done using Conserved Domains (NCBI). Upper case amino acids are aligned and 
lower case grey amino acids are unaligned. The red to blue color scale shows the degree of conservation 
with red representing highly conserved. Gi number represents the different species. Potential interaction 
domains of RGC-32 and CDK1 or Plk1 are underlined as pink and black. Amino acids framed are the 
mutated residues for CDK1 and Plk1 binding (also see Figure 4-7).    
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Figure 4-8. Mutated residues in RGC-32 for CDK1 or Plk1 binding (also see Figure 4-10). 
A. Mutation of RGC-32 (F68A, F70A) for CDK1 binding. B. Mutation of RGC-32 (Y33A,K41E, R42E, R43E) 
for Plk1 binding. 
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Figure 4-9. In vitro interaction of RGC-32 mutant with CDK1. 
Glutathione agarose beads or beads bound to GST, GST-RGC-32 WT, truncations or mutant were mixed 
with BJAB total cell lysates. A and C. SDS-PAGE gel analysis of GST, GST-RGC-32 WT, truncations and 
mutant used in GST pull-down assay. B and D. Western blot analysis of interaction of RGC-32 mutant with 
CDK1. E. The intensity of bands was quantified using Licor and relative to the WT. This figure shows the 
mean of 2 independent experiments.  
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For Plk1 binding, Y33 K41 R42 R43 mutating to A33 E41, 42 and 43, which 
were present in the predicted helix, decreased the binding activity for PLK1 to 
around 40% compared to RGC-32 wildtype (Figure 4-10C). Since this was the 
result of one experiment, this would need to be repeated to confirm this 
observation and due to time constraints this was not possible. 
 
4.5 RGC-32 can interact with Spc24 
During the course of this study, we identified the third α-helix (Figure 3-1) has a 
homology to the N terminus of histone-fold protein Cnn1 using HHpred (Figure 
4-11). It has been shown that Cnn1 is bound as an α-helix in a hydrophobic cleft 
at the interface between Spc24 and Spc25 (Malvezzi et al., 2013). Spindle pole 
component 24 and 25 (Spc24-25) are Ndc kinetochore complex component and 
play a role in the attachment of kinetochore to microtubule (Malvezzi et al. 2013) 
(see section 1.1.4). Next, we tested if there was an interaction of RGC-32 and 
Spc24. We found that GST-tagged RGC-32 was able to pull down Spc24 
(Figure 4-12). RGC-32 truncation mutants were used to identify the domains 
required for binding to Spc24. Only truncation 1-25 failed to pull down Spc24. 
All other truncations (1-50, 1-75 and 1-100) and full length RGC-32 pulled down 
Spc24 successfully (Figure 4-12). Hence amino acid residues between 25 and 
50 in the RGC-32 are the required for Spc24 binding (Figure 4-13). RGC-32 has 
been reported to concentrate in centrosomes and spindle poles during 
prometaphose and metaphase (Saigusa et al. 2007). Our results suggest that 
RGC-32 might play a role in the attachment of kinetochore to microtubule by 
interacting with Spc24.  
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Figure 4-10. In vitro interaction of RGC-32 mutant with Plk1. 
Glutathione agarose beads or beads bound to GST, GST-RGC-32 WT, truncations or mutant were mixed 
with BJAB total cell lysates. A. SDS-PAGE gel analysis of GST, GST-RGC-32 WT, truncations and mutant 
used in GST pull-down assay. B. Western blot analysis of interaction of RGC-32 mutant with Plk1. C. The 
intensity of bands was quantified using Licor and relative to the WT. This figure shows data of one 
experiment.  
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Figure 4-11. Sequence alignment of RGC-32 and Cnn1 using HHpred. 
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Figure 4-12. In vitro interaction of RGC-32 truncations with Spc24. 
Glutathione agarose beads or beads bound to GST, GST-RGC-32 FL or truncations were mixed with 
BJAB total cell lysates. A. SDS-PAGE gel analysis of GST, GST-RGC-32 FL and truncations used in pull-
down assay. B and C. Western blot analysis of interaction of RGC-32 truncations with Spc24.  
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Figure 4-13. Summary of potential RGC32 binding domains with Spc24. 
RGC-32 was shown as blue bars and three predicted helical regions in RGC-32 were shown as red bars.   ̶ 
means there is no binding between RGC-32 truncations and Spc24 and + means there is binding 
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4.6 Characterisation of stable RGC-32 expressing cell lines 
Expression of RGC-32 has been shown to promote S and M phase entry of 
smooth muscle cells following G1 arrest (Badea et al. 2002). Our group 
demonstrated that stable overexpression of RGC-32 alone is sufficient to 
disrupt the G2/M checkpoint (Schlick et al. 2011). Unfortunately, continued 
culture of the stable cell lines overexpressing RGC-32 that were generated for 
this work led to the loss of their cell-cycle disruption phenotype.  
 
We therefore set out to generate stable cell lines expressing inducible RGC-32 
to avoid the accumulation of compensatory mutations. RGC-32 was cloned into 
pRTS-1 vector (Figure 2-2) between SfiI restriction sites to replace the 
luciferase gene. This Doxycycline-dependent expression system has a 
bidirectional promoter which allows the expression of two genes, eGFP and the 
gene of interest. The expression of the gene of interest is switched on or off by 
adding doxycycline or not.  This vector carries the EBV plasmid origin of 
replication (oriP) and EBNA1 which binds to oriP and maintains episomal 
replication of the episome to daughter cells (Bornkamm et al. 2005).  
4.6.1 DNA test using HEK293T cells   
Initially, RGC-32 was cloned into this vector and transfected into the EBV 
negative BL cell line DG75. Stable cell lines were selected by limited dilution in 
the presence of 200 µg/ml hygromycin. The expressions of EBNA 1 and RGC-
32 were not detected in total cell lysates by western blotting (data not shown). 
Therefore we tested the DNA for transfection using HEK293T cells which have 
higher transfection efficiency than DG75.  
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HEK293T cells were transiently transfected with pRTS1 empty vector or 
pRTS1-RGC-32 (old and new) and Doxycline (DOX) was add 24 hours post-
transfection to induce the expression of eGFP and luciferase or RGC-32. 
Luciferase assay showed that addition of Doxycline induced the expression of 
eGFP (Figure 4-14). Then we tested using old DNA which had been stored at -
20°C after being made and new DNA which were used without storage -20°C to 
see if the way storing DNA made difference for transfection. Flow cytometry 
experiments showed that transfection efficiency is higher using new DNA than 
old DNA (Figure 4-15) and Western blot analysis confirmed the expression of 
EBNA1 and RGC-32 using both DNAs (Figure 4-16).  
 
 
4.6.2 Stable Akata cell line expressing RGC-32  
4.6.2.1 Optimisation of DOX induction 
Akata cells were transfected with pRTS1 empty vector or pRTS1-RGC-32 and 
then cultivated in growth medium. The hygromycin concentration in medium 
was increased gradually to 100 µg/ml by replacing the medium with hygromycin 
containing medium weekly. Within the next 2-4 weeks, hygromycin resistant 
cells grew out.  
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Figure 4-14. Verification of DNA used in making stable cell lines using HEK293T cells.  
Luciferase assay of with/without DOX induction in HEK293T cells transfected with pRTS-1 vector. This 
figure shows the mean of 2 independent experiments.  
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Figure 4-15. FACS analysis of transiently transfected HEK293T cells.  
HEK293T cells were transiently transfected with old pRTS-1-RGC-32 (DNA had been stored at -20 °C 
before transfection) and new pRTS-1-RGC-32 (DNA was used in transfection after made). 3 µg DNA was 
transfected using Effectene Transfection Reagent (QIAGEN). Cells were harvested 48 hours and the 
percentage eGFP-positive cells determined by flow cytometry. 
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Figure 4-16. Western blot analysis of EBNA 1 and RGC-32 expression in HEK293T.  
HEK293T cells were transiently transfected with old DNA (DNA had been stored at -20 °C before 
transfection) and new DNA (DNA was used in transfection after made). Cells were harvested and total cell 
lysates of -/+ DOX induction were separated on a gel. The Mutu III cell line total cell lysate was used as a 
positive control for EBNA 1 and RGC-32 expression. 
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To optimise the expression of RGC-32 in Akata cells, 1 or 2 µg/ml Doxycycline 
and 24 or 48 hours induction time were tested. Western blotting analysis 
showed that the expression of both EBNA 1 and RGC-32 were higher at 48 
hours than 24 hours (Figure 4-17). More RGC-32 was expressed using 1 µg/ml 
Doxycycline induction compared to 2 µg/ml at 48 hours (Figure 4-17). 1 µg/ml 
Doxycycline and 48 hours induction time were used for further experiments.  
 
4.6.2.2 The effects of stable RGC-32 overexpression  
 
To investigate the effect of RGC-32 overexpression on the G2/M checkpoint, 
etoposide, a topoisomerase II inhibitor, was used to induce double stranded 
DNA breaks and arrest cells in G2. DOX was added to induce RGC-32 and then 
etoposide was added 48 hours post DOX induction. Cells without DOX 
induction are used as control. Western blotting analysis confirmed the 
expression of EBNA 1 and RGC-32 in cells before and after etoposide 
treatment (Figure 4-18). The proportion of cells in each cell cycle phase was 
analysed after 8, 24 and 48 hours etoposide treatment. DOX induction 
increased apoptosis, such as a sub-G1 population by 8% without etoposide 
(Figure 4-19).  The results showed that compared to Akata cells not 
overexpressing RGC-32, Akata cells overexpressing RGC-32 cells displayed an 
increased proportion of cells in G0/G1 and a decreased proportion of cells in 
G2/M (Figure 4-19). RGC-32 overexpressing Akata cells showed 2%, 5% and 
13% increase in the G0/G1 phase after 8, 24 and 48 hours etoposide treatment 
respectively, compared with control cells (Figure 4-20). The G2/M population of 
Akata cells expressing RGC-32 decreased 6%, 25% and 14% after 8, 24 and  
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Figure 4-17. Western blotting analysis of stable Akata cell lines after DOX induction.  
Akata cells were stable transfected with pRTS-1α empty vector or pRTS-1α RGC-32 then harvested 24 or 
48 hours post doxycycline treatment (1 or 2 µg/ml) and whole cell lysates of -/+ DOX induction were 
separated on a gel. The Mutu III cell line is a positive control for EBNA 1 and RGC-32 expression. Actin is 
a loading control.   
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Figure 4-18. Western blotting analysis of stable Akata cells after etoposide treatment. 
Akata cell lines stably expressing RGC-32 were exposed to 400 nM etoposide for 8, 24 and 48 hours after 
48 hours of DOX induction. Whole cell lysates were separated on a gel. The IB4 cell line is a positive 
control for EBNA 1 and RGC-32 expression. Actin is a loading control.   
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Figure 4-19. FACS analysis of stably transfected Akata cells after etoposide treatment. 
Akata cell lines stably expressing RGC-32 were exposed to 400 nM etoposide for 0, 8, 24 and 48 hours 
(n=1). Cells were stained with propidium iodide to visualise cell cycle distribution.  
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Figure 4-20. Percentage change of Akata cells -/+ etoposide in each phase. 
Akata cell lines stably expressing RGC-32 were exposed to 400 nM etoposide for 8, 24 and 48 hours. The 
percentage change of cells -/+ etoposide in each phase was relative to control cells. 
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48 hours etoposide treatment respectively, compared with control cells (Figure 
4-20). It indicated RGC-32 disrupted G2/M checkpoint in Akata cell line which 
was consistent with our previously published data in BJAB and DG75 cell lines 
(Schlick et al. 2011). It is possible that RGC-32 expression activates CDK1 
activity which results that the cells override etoposide-induced G2 arrest. 
 
4.6.3 Stable HEK293 cell line expressing RGC-32  
4.6.3.1 Optimisation of DOX induction 
HEK293 cells were transfected with pRTS1 empty vector or pRTS1-RGC-32 
and then cultivated in growth medium. The hygromycin concentration in medium 
was increased gradually to 50 µg/ml by replacing the medium with hygromycin 
containing medium weekly. Within the next 2-4 weeks, hygromycin resistant 
cells grew out.  
 
To optimise the expression of RGC-32 in the HEK293 cell line, 0.5, 1 or 2 µg/ml 
Doxycycline and 8, 24 or 48 hours induction time were tested. Western blot 
showed that the expression of both EBNA 1 and RGC-32 was higher at 48 
hours than 8 and 24 hours (Figure 4-21). More RGC-32 was expressed using 1 
µg/ml Doxycycline induction compared to 0.5 and 2 µg/ml at 48 hours (Figure 4-
21). 1 µg/ml Doxycycline and 48 hours induction time were used for further 
experiments. 
 
4.6.3.2 The effects of stable RGC-32 overexpression  
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Figure 4-21. Western blotting analysis of stable HEK293 cell lines after DOX induction.  
HEK293 cells were stable transfected with A. pRTS-1α empty vector or B. pRTS-1α RGC-32 then 
harvested 8, 24 or 48 hours post doxycycline treatment (0.5, 1 or 2 µg/ml) and whole cell lysates of -/+ 
DOX induction were separated on a gel. The Mutu III cell line is a positive control for EBNA 1 and RGC-32 
expression. There is some problem with sample at 24 hours with 1 µg/ml DOX as no expression of both 
EBNA 1 and RGC-32 had been shown.  
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Western blotting analysis confirmed the expression of EBNA 1 at 8, 24 and 48 
hours and RGC-32 at 8 and 48 hours before and after etoposide treatment 
(Figure 4-22). There was very little RGC-32 expression at 24 hours. The 
proportion of cells in each cell cycle phase was analysed after 8, 24 and 48 
hours of etoposide treatment (Figure 4-23). The results showed that HEK293 
cells did not arrest at G2/M after 8, 24 or 48 hours etoposide treatment (Figure 
4-24). It is possible the concentration of etoposide was not high enough to 
arrest the cells, but due to time constraints I was not able to perform any further 
titrations.   
 
4.6.4 Stable HeLa cell line expressing RGC-32  
4.6.4.1 Optimisation of DOX induction 
HeLa cells were transfected with pRTS1 empty vector or pRTS1-RGC-32 and 
then cultivated in growth medium. The hygromycin concentration in medium 
was increased gradually to 100 µg/ml by replacing the medium with hygromycin 
containing medium weekly. Within the next 2-4 weeks, hygromycin resistant 
cells grew out.  
 
To optimise the expression of RGC-32 in HeLa cells, 1 or 2 µg/ml Doxycycline 
with 24 or 48 hours induction time were tested. Western blotting analysis 
showed that the expression of both EBNA 1 and RGC-32 were similar at 24 and 
48 hours, but less actin was expressed when induction time was 48 hours 
compared to 24 hours (Figure 4-25). More RGC-32 was expressed using 1 
µg/ml Doxycycline induction compared to 2 µg/ml at 24 or 48 hours (Figure 4- 
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Figure 4-22. Western blotting analysis of stable HEK293 cells after etoposide treatment. 
HEK293 cell lines stably expressing RGC-32 were exposed to 1 µM etoposide for 8, 24 and 48 hours after 
48 hours of DOX induction. Whole cell lysates were separated on a gel. The Mutu III cell line is a positive 
control for EBNA 1 and RGC-32 expression. Actin is a loading control.   
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Figure 4-23. FACS analysis of stably transfected HEK293 cells after etoposide treatment. 
HEK293 cell lines stably expressing RGC-32 were exposed to 1 µM etoposide for 0, 8, 24 and 48 hours. 
Cells were stained with propidium iodide to visualise cell cycle distribution.  
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Figure 4-24. Percentage change of HEK293 cells -/+ etoposide in each phase. 
HEK293 cell lines stably expressing RGC-32 were exposed to 1 µM etoposide for 8, 24 and 48 hours. The 
percentage change of cells -/+ etoposide in each phase was relative to control cells. 
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Figure 4-25. Western blotting analysis of stable HeLa cell lines after DOX induction.  
HeLa cells were stable transfected with pRTS-1α empty vector or pRTS-1α RGC-32 then harvested 24 or 
48 hours post doxycycline treatment (1 or 2 µg/ml) and whole cell lysates of -/+ DOX induction were 
separated on a gel. The GM12878 cell line is a positive control for EBNA 1 and RGC-32 expression. Actin 
is a loading control.   
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25). 1 µg/ml Doxycycline and 48 hours induction time were used for further 
experiments. 
 
4.6.4.2 The effects of stable RGC-32 overexpression  
Western blot confirmed the expression of EBNA 1 and RGC-32 before and after 
etoposide treatment (Figure 4-26). The proportion of cells in each cell cycle 
phase was analysed after 8, 24 and 48 hours of etoposide treatment (Figure 4-
27). The HeLa cells expressing RGC-32 were arrested at G2 phase only at 48 
hours, but the expression of RGC-32 did not change the proportion of cells in 
each phase (Figure 4-28). Interestingly, Saigusa et al. has shown the similar 
results of HeLa cells overexpressing RGC-32 protein display simultaneous 
transition into G2/M phase from G1, but delayed transition into G1 phase from 
G2/M phase compared with control cells (Saigusa et al. 2007). Due to time 
constraints, I was not able to perform any further titrations of etoposide 
concentration.  
 
4.7 Discussion 
In this chapter, which regions are involved in the CDK1 and Plk1 interaction and 
the mechanism of RGC-32 disrupting cell cycle were investigated. Previously 
RGC-32 was found to associate with the recombinant CDK1/Cyclin B1 complex 
in vitro (Badea et al. 2002). Our results provided the first evidence that RGC-32 
interacted with CDK1 in B-cells but interestingly not with Cyclin B1. It is possible 
that activation by RGC-32 is Cyclin-independent or RGC-32 competing with  
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Figure 4-26. Western blotting analysis of HeLa stable cells after etoposide treatment. 
HeLa cell lines stably expressing RGC-32 were exposed to 1 µM etoposide for 8, 24 and 48 hours after 48 
hours of DOX induction. Whole cell lysates were separated on a gel. The IB4 cell line is a positive control 
for EBNA 1 and RGC-32 expression. Actin is a loading control.   
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Figure 4-27. FACS analysis of stably transfected HeLa cells after etoposide treatment. 
HeLa cell lines stably expressing RGC-32 were exposed to 1 µM etoposide for 0, 8, 24 and 48 hours. Cells 
were stained with propidium iodide to visualise cell cycle distribution.  
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Figure 4-28. Percentage change of HeLa cells -/+ etoposide in each phase. 
HeLa cell lines stably expressing RGC-32 were exposed to 1 µM etoposide for 8, 24 and 48 hours. The 
percentage change of cells -/+ etoposide in each phase was relative to control cells. 
 
 
 
 
 
 
 
4-131 
 
Cyclin B1 for CDK1. It indicated that the interaction of RGC-32 and CDK1 was 
specific. RGC-32 was shown to activate CDK1 in a manner of dependent on its 
Thr 91 phosphorylated by CDK1 (Badea et al. 2002). Mutation of RGC-32 
protein at threonine 91 did not show any change compared to the ability of 
RGC-32 wildtype to bind CDK1 in our pull-down assays. So it might suggest 
that phosphorylation of Thr 91 in RGC-32 is important for its activity but not its 
binding with CDK1. 
 
To further identify the potential regions of RGC-32 binding to CDK1, RGC-32 
truncations were constructed based on secondary prediction derived using 
JPred. Pull-down results showed 50-75 aa was the potential domain involved in 
CDK1 binding which didn't include any predicted α-helix. Next we could do 
kinase assays using these truncations to map the domain which is crucial for 
increasing CDK1 activity.  
 
RGC-32 was shown to interact with Plk1 upon phosphorylation by it in vitro but 
not with CDK1, indicating another possible way in which RGC-32 level mediates 
cell cycle control (Saigusa et al. 2007). During the G2/M transition, Plk1 
phosphorylates CDK1/Cyclin B and Cdc25 leading to mitotic entry (Kumagai 
and Dunphy 1996). We showed that RGC-32 bound to both CDK1 and Plk1. In 
our pull-down results, GST-tagged RGC-32 interacted with Plk1 in B-cells and 
the potential binding region identified as 25-50 aa which included one predicted 
α-helix. To test if RGC-32 binds to CDK1 and Plk1 at the same time, we could 
purified them separately then do gel filtration chromatography which is a 
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technique to separate proteins based on molecular size: the larger molecules 
will elute before the smaller ones.  
 
In the West lab, overexpression of RGC-32 in two different B-cell backgrounds 
previously shown to disrupt the G2/M checkpoint (Schlick et al. 2011) which 
indicated a role of it in EBV-mediated cell cycle deregulation. It has been shown 
that overexpression of RGC-32 alone can disrupt the G2/M checkpoint in B-cell 
lines (Schlick et al. 2011). But the cell cycle disruption phenotype was reduced 
in the following experiments. The attempt of making stable DG75 
overexpressing RGC-32 did not work due to the low transfection efficiency. So 
stable cell line overexpressing RGC-32 was make in Akata, an EBV positive BL 
cell line. It was confirmed that RGC-32 alone can disrupt the G2/M checkpoint. 
Combined with the pull-down experiments which showed that RGC-32 can 
interact with CDK1 and Plk1 which are important in G2/M checkpoint, it implied 
the possible way RGC-32 interrupting G2/M checkpoint is through CDK1 or Plk1. 
This stably expressing RGC-32 Akata cell line can be used to test more drugs 
to see their effect on cell cycle. Also the concentration of drugs using to arrest 
HEK293 and HeLa cells need to be titrated for further investigation of RGC-32 
expression on cell cycle disruption.   
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5 Mechanism of RGC-32 expression on 
transcriptional level 
5.1 Introduction  
RGC-32 is expressed at the RNA level in many different human tissues 
including artery, bladder, brain, breast, cervix, colon, heart, kidney, lung, liver, 
lung and pancreas. RGC-32 is overexpressed at the RNA level in multiple 
human tumours including bladder, breast, colon, lung, prostate and ovaries 
(Kang et al. 2003, Donninger et al. 2004, Fosbrink et al. 2005). Interestingly 
West’s lab has shown that RGC-32 protein is not expressed in EBV-negative 
and EBV-positive latency I B cell lines, however highly expressed in EBV-
positive latency III B cell lines (Figure 5-1A). The RGC-32 mRNA expression 
has shown the opposite since it is higher in some EBV-negative and EBV-
positive latency I B cell lines than in EBV-positive latency III B cell lines (Figure 
5-1B). Although RGC-32 mRNA expression is low in latency III cell lines, 
EBNAs may keep it high enough so RGC-32 protein can be made. It suggests 
that EBNAs might play a role in regulation of RGC-32 expression in EBV-
infected cells. Therefore, this chapter aims to investigate the potential role of 
EBV latency III gene products in the regulation of RGC-32 mRNA expression.  
 
Figure 5-2 summarised how RGC-32 mRNA expression is regulated by EBV 
transcription factors in different cell line backgrounds. RGC-32 mRNA 
expression is negatively regulated by EBNA 2 in EBV-negative B cell line (Maier 
et al. 2006). Two EBV-negative B cell lines were used to perform a screen for  
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Figure 5-1. RGC-32 expression on protein and mRNA levels in different types of EBV 
latency (Schlick et al. 2011).  
A. Western blotting analysis of RGC-32 protein expression in EBV negative and positive B cell lines. Actin 
is used as a loading control. B. q-PCR analysis of RGC-32 mRNA expression in EBV negative and 
positive B cell lines. Results show the mean of 3 independent experiments +/- standard deviation. This 
figure was taken from (Schlick et al. 2011). 
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Figure 5-2.  Summary of how RGC-32 is regulated by EBNA 2 or EBNA 3A, 3B or 3C in 
different cell background.  
Orange indicates that the EBV gene product has a negative effect on the expression of RGC-32 and blue 
indicates that the EBV product has a positive effect on the expression of RGC-32. The 2.95-fold change of 
RGC-32 downregulation in EBNA 3A deficient LCL is the average of 2 EBNA 3A mutants from all 3 donors.  
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EBNA 2 targets and both of them expressed a chimeric EBNA 2 protein fused to 
estrogen receptor EBNA 2 (ER/EBNA 2). The expression of EBNA 2 can be 
switched on and off by estrogen. It has shown that RGC-32 expression is 
decreased after EBNA 2 activation (Maier et al. 2006). 
 
RGC-32 is positively regulated by EBNA 3A, 3B and 3C in LCLs (Hertle et al. 
2009, Skalska et al. 2013, White et al. 2010) (see Figure 5-3). The West’s lab 
has shown that RGC-32 is positively regulated in EBV-negative B cell line 
(McClellan et al. 2012). We carried out a microarray analysis of the effects of 
EBNA 3C on cellular gene expression in BJAB cell line which expresses higher 
levels of EBNA 3C than are present in latently infected cells. RGC-32 
expression is upregulated with higher EBNA 3C expression.  
 
Figure 5-3 showed the dotplots analysis of RGC-32 expression regulation of by 
EBNA 3A (Figure 5-3A), 3B (Figure 5-3B) and 3C (Figure 5-3C) proteins in 
LCLs. This dotplots analysis is done by Professor Martin Allday’s group 
(http://www.epstein-barrvirus.org.uk/).  
 
Two different EBNA 3A mutant viruses were used in genome wide analysis of 
cellular genes differentially expressed by EBNA 3A positive and negative LCLs 
(Hertle et al. 2009) (Figure 5-3A). Mutant A (MutA) carried a deletion of the 
second exon of EBNA 3A and mutant B (MutB) has the entire EBNA 3A coding 
sequence deleted. It has shown that RGC-32 downregulated 2.95-fold in EBNA  
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Figure 5-3.  Dotplots analysis of RGC-32 mRNA regulation by EBNA 3A, 3B and 3C in 
LCLs by Professor Martin Allday group (http://www.epstein-barrvirus.org.uk/).  
Shapes of dots in the plot represent different donors. WT-BAC is wild type B95.8 bacterial artificial 
chromosome (BAC) EBV. A. RGC-32 expression when EBNA 3A WT is expressed (orange) or EBNA 3A 
is mutated (dark and light blue) (Hertle et al. 2009). MutA carries a deletion of the second exon of EBNA 
3A and mutB is lack of the whole EBNA 3A coding sequence. B. RGC-32 expression when EBNA 3B is 
expressed (orange) or EBNA 3B is knock-out (pink) (White et al. 2010). 3BKO is EBNA 3B knockout-
infected LCLs. C. RGC-32 expression when EBNA 3C is expressed (orange) or EBNA 3C is withdrawn 
(blue) (Skalska et al. 2013). HT plus represents there is EBNA 3C expression and withdrawn represents 
there is no EBNA 3C expression.  
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3A deficient LCLs. This fold in raw data is the average of two EBNA 3A mutants 
for all three donors (Hertle et al. 2009). Data reanalysed by Allday group are 3A 
deficient LCLs. This fold in raw data is the average of two EBNA 3A mutants for 
all three donors (Hertle et al. 2009). Data reanalysed by Allday group are shown 
with wild type EBV-BAC LCLs compared to the mutants as two independent 
groups (http://www.epstein-barrvirus.org.uk/arrays2.php). So EBNA 3A has a positive 
effect of RGC-32 mRNA expression. 
 
White et al. have shown RGC-32 expression is downregulated in EBNA 3B 
knock-out LCLs (White et al. 2010) (Figure 5-3B). Wild type EBV LCLs and 
EBNA 3B knockout (3BKO) were generated by infecting primary B cells with the 
B95-8 strain BAC (WT-BAC) and EBNA 3B exon2 deleted viruses from three 
donors (http://www.epstein-barrvirus.org.uk/arrays2.php).  
 
3CHT virus, which is an EBV containing an EBNA 3C fused at its C terminus to 
a modified estrogen receptor which controls EBNA 3C expression dependent on 
the presence of 4-hydroxy tamoxifen (HT), were used in a microarray (Skalska 
et al. 2013) (Figure 5-3C).  Figure 5-4 showed the microarray strategy. 4HT was 
washed out of cell lines that had been established in the presence of 4HT (day 
0). These cells were cultured in the absence of 4HT and same cell line in the 
presence of 4HT. After 32 days, cell with 4HT were split into two and one 
culture washed out of 4HT. Those cells grown in the absence of 4HT were also 
split into two. 4HT was re-added to one culture. At day 37, RNA was harvested 
for microarray analysis. RGC-32 expression is upregulated when EBNA 3C  
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Figure 5-4. Schematic representation of microarray results in Figure 5-3C.  
Horizontal lines indicate the growth either in the absence (blue lines) or presence (red lines) of 4HT. Block 
arrows represent the time points at which RNA was harvested for Microarray analysis. This figure was 
taken from (Skalska et al., 2013).  
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expression is restored by adding 4HT (http://www.epstein-
barrvirus.org.uk/arrays2.php). 
 
Microarray analysis indicates EBV-encoded EBNAs play a role in regulation of 
RGC-32 mRNA expression. To study how RGC-32 is regulated by EBNAs and 
whether this regulation is direct or indirect, we examined ChIP-sequencing data 
we obtained for EBNA 2, 3A, 3B and 3C to detect binding sites on RGC-32 
locus in Mutu III cell line (McClellan et al. 2013) (Figure 5-5). Mutu III is a 
Burkitt’s lymphoma cell line expressing the full panel of EBV latent genes.  
 
5.2 EBNA 2 binds to the second intron of RGC-32 in Mutu III 
cell line 
ChIP-seq data analysis detected four binding sites for EBNA 2 (E2, E4, E6 and 
E8) at the second intron of RGC-32 gene (Figure 5-5). To verify that EBNA 2 is 
able to associate with these binding sites, ChIP-qPCR was carried out to 
confirm the binding by using primer sets located at the binding sites. EBNA 2 
binding at the transcription start site of PPIA (peptidylprolyl isomerase 1) and 
the previously characterized CTBP2 binding site were used as negative and 
positive binding controls (McClellan et al. 2013). Our group has shown that 
EBNA 3A, 3B and 3C bind the C-terminal binding protein 2 (CTBP2) enhancer 
(McClellan et al. 2013). EBNA 2 binding at all four sites was confirmed by ChIP-
qPCR (Figure 5-6). These data indicate that EBNA 2 may repress RGC-32 
transcription directly by binding to intronic regulatory sites. To examine the 
potential role for the second intron of RGC-32 as a regulatory region, we  
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Figure 5-5. EBNA 3s and EBNA 2 binding at the RGC-32 locus.  
EBNA 2 and EBNA 3 proteins ChIP-seq reads in Mutu III cells and H3K27Ac signals in GM12878 from 
ENCODE. RGC-32 runs left to right in the human genome. Numbering indicates the potential binding sites 
in Mutu III cells (McClellan et al. 2013)  
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Figure 5-6. ChIP qPCR analysis of EBNA 2 binding in Mutu III cells.  
Precipitated DNA was analysed using to primer sets designed at the binding sites (2, 3, 4, 6 and 8) or 
trough regions (1, 5, 7 and 9). 3 µl DNA was added to a SYBR master mix containing GoTaq qPCR Master 
Mix (Promega), forward and reverse primers and sterile water to a final volume of 15 µl. EBNA 2 binding at 
the transcription start site of PPIA and CTBP2 were used as negative and positive control respectively. 
The mean percentage input signals of two independent ChIP experiments are shown after subtraction of 
no antibody controls (n=2).  
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examined publicly available histone modification data. ChIP-seq analysis of the 
active chromatin mark, histone H3 lysine 27 acetylation was high in the 
GM12878 LCL in the region bound by enhancer 2 (green box in figure 5-5). 
 
5.3 EBNA 2 has no effect on the RGC-32 promoter reporters 
that contain enhancer peaks 
To examine whether EBNA 2 regulates RGC-32 mRNA expression via these 
binding sites, each of the four binding sites were cloned into luciferase reporter 
constructs containing the RGC-32 promoter -1150 to +62. DG75 cells were 
transiently transfected using differenct amounts of EBNA 2 expressing plasmid 
pSG5-EBNA 2 (0, 10 20 µg). Positive control experiments were carried out with 
C promoter-reporter constructs. EBNA 2 has been shown to stimulate the 
expression of C promoter, the major latency promoter (Woisetschlaeger et al. 
1991). Negative control experiments were carried out with pGL3 Basic which 
has no promoter and pGL3 RGC-32 which has the RGC-32 promoter only. The 
luciferase assays did not show any significant effect of EBNA 2 on transcription 
form the RGC-32 promoter (Figure 5-7).  
 
5.4 EBNA 3C binds to RGC-32 in Mutu III cell line 
We identified a single binding site (E2) for EBNA 3 proteins in the second intron 
of RGC-32 (Figure 5-3). To confirm the ChIP-sequencing data, ChIP-qPCR was 
carried out to see which EBNA binds. As our ChIP-seq analysis was carried out 
using an antibody that precipitated all three EBNA 3 proteins, ChIP-qPCR in  
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Figure 5-7. Luciferase analysis of RGC-32 enhancer elements.   
DG75 cells (EBV negative cell lines) were transiently transfected with different amounts of firefly luciferase 
reporter plasmid containing A. the C promoter (positive control), B. pGL3 basic (no promoter), C. the RGC-
32 promoter alone, D-G. the RGC-32 promoter in the presence of each enhancer cloned upstream E2, E4, 
E6 and E8. Results shows 3 independent experiments +/- standard deviation in which RGC-32 promoter 
activation was measured and are displayed relative to the 0 µg EBNA 2 negative control (n=3).  
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Mutu III cells was carried out to examine the binding of EBNA 3A, 3B and 3C 
proteins individually using anti-EBNA 3A, anti-EBNA 3B and anti-ENBA 3C 
antibodies. We found that only EBNA 3C bound to RGC-32 intron at enhancer 2 
(Figure 5-8). It is possible that EBNA 3C might activate RGC-32 transcription by 
binding to enhancer 2. 
 
5.5 Discussion 
Our results showed that EBNA 2 binds to the second intron of RGC-32 in the 
Latency III BL cell line Mutu III, but no regulation was detected using reporter 
assays. The possible reason is those binding sites do not control the expression 
of RGC-32 mRNA individually, therefore we could investigate whether this 
whole region respond to EBNA 2. On further examination of the data we 
identified a cluster of EBNA 2 binding sites at 20 kb downstream from RGC-32 
gene (blue box in figure 5-9). EBNA 2 and 3 proteins have been shown to 
regulate cellular genes through their associations with long distance regulatory 
elements (McClellan et al. 2012, McClellan et al. 2013). Next, the distal binding 
sites need to be confirmed by ChIP-qPCR. It would be interesting to investigate 
whether these binding sites control the expression of RGC-32 mRNA using 
reporter assays.  
 
To investigate whether EBNA 2 expression alters expression of other genes, 
microarray analysis could be performed using EBNA 2 knockout LCLs. RGC-32 
mRNA expression is negatively regulated by EBNA 2 in EBV-negative B cell 
line (Maier et al. 2006). It is possible to repress RGC-32 expression by knocking 
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Figure 5-8. ChIP qPCR analysis of EBNA 3A (A.), EBNA 3B (B.) and EBNA 3C (C.) binding 
at RGC-32 in Mutu III cells.  
ChIPed DNA was used according to primer sets designed at the binding sites (2 and 3) or trough regions 
(1). EBNA 3s binding sites at the preciously characterized T6 which is a trough region adjacent to the 
binding sites and shows very low signal (Gunnell et al. 2016) were used as negative control. Binding sites 
CTBP2 were used as positive control. The mean percentage input signals of two independent ChIP 
experiments are shown -/+ standard deviation after subtraction of no antibody controls. 
5-147 
 
  E2 E4 E6 E8 
  SPI1 (1000) MTA3 (308) ZEB1 (127) POLR2A (1000) 
  RUNX3 (302) MAZ (179) CEBPB (283) BCL3 (216) 
    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
NFATC1 (517) EP300 (272)   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  NFIC (269) RUNX3 (1000) 
  RAD21 (185) SPI1 (344) 
  MEF2A (181) TAF1 (336) 
  RUNX3 (871) BCLAF1 (208) 
  PAX5 (685) ELF1 (695) 
  EGR1 (237) NFIC (722) 
  SP1 (160) MTA3 (443) 
  EBF1 (275) YY1 (237) 
  TCF12 (463) IRF4 (459) 
Transcription   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
BHLHE40 (255) 
  PAX5 (522) 
 factors  FOXM1 (590) 
  POU2F2 (270) 
(signal intensity) EBF1 (259) 
  EGR1 (156) 
  MEF2A (280) 
  ATF2 (577) 
  ETS1 (143) 
  TCF3 (803) 
  NFATC1 (450) 
  SRF (273) 
  BATF (1000) 
  PBX3 (218) 
  RAD21 (190) 
  TCF12 (869) 
  BCL3 (430) 
  SP1 (427) 
  BCL11A (441) 
 
Table 5-1. Transcription factors binding at E2, E4, E6 or E8 (Genome browser).  
Transcription factors ChIP-seq reads in GM12878 cells (McClellan et al., 2013). The signal intensity is 
showed in brackets and the green highlight represents the highest scoring site of a Factorbook-identified 
canonical motif for the corresponding factor.   
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Figure 5-9. EBNA2, 3A, 3B, 3C and RBP-Jκ binding at the RGC-32 locus.  
EBNA 2, 3A, 3B and 3C ChIP-sequencing reads in Mutu III (McClellan et al. 2013), H3K27me3 signals in 
the EBV-immortalised LCL, GM12878 from ENCODE and RBP-Jκ ChIP-sequencing reads in the EBV-
immortalised LCL, IB4 detected by MACS (Zhao et al., 2011). RGC-32 runs left to right in the human 
genome. The black bars indicate the wholly enriched region from start to end. Summits indicate the 
highest pile up point within the peak region.  
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off a better activator. I examined the ChIP-seq data to identify other genes 
binding at the second intron of RGC-32 gene and summarised in table 5-1. The 
genes binding at E2, E4, E6 and E6 are present and the binding intensity is 
shown in brackets. The maximum of signal intensity is 1000 which represents 
the strongest binding and the genes highlighted in green are the highest scoring 
site of identified motif for the corresponding factor. RUNX3 binds to enhancer 2, 
4 and with high scoring of binding. Our previous data show that RUNX3 
represses the expression of RUNX 1 and RUNX1 activates expression of RGC-
32 mRNA (Gunnell et al. 2016). It would be interesting to investigate whether 
expression of RUNX3 regulates RGC-32 expression. Also we examined publicly 
available histone modification data, we identified some signal of Histone 3 
lysine 27 trimethylation (H3K27m3) from ENCODE (black box in figure 5-9) 
which is associated with lower of transcription and there defined as repression 
mark. Our previous date show that RGC-32 mRNA level is low in latency III cell 
lines (Schlick et al. 2011), so it is possible that mRNA expression of RGC-32 is 
repressed through histone modification in this region.  
 
EBNA 3C binds to RGC-32 in Mutu III at enhancer 2. It has been shown that 
EBNA 3C bound strongly to the p14ARF promoter through 
SPI1/IRF4/BATF/RUNX3, establishing RBPJ-κ, Sin3A-, and REST-mediated 
repression (Jiang et al. 2014). Interestingly SPI1 (PU.1), IRF4, BATF and 
RUNX3 all bind at the second intron of RGC-32 gene which suggests it is 
possible that EBNA 3C might form a complex with them to control RGC-32 
transcription. But the low expression of IRF4 in DG75 cell line, used for 
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luciferase assays, might abolish the association between EBNA 3C and RGC-
32 gene. 
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6 Discussion and future work 
6.1 What is the mechanism of CDK1 activation by RGC-32? 
RINGO/Speedy has been shown to function like RGC-32 in cell cycle 
progression (Gastwirt et al. 2007). RINGO/Speedy was initially described as a 
protein which induces the G2/M transition during oocyte maturation (Lenormand 
et al. 1999, Ferby et al. 1999). It was later shown to be able to activate CDK1 
and CDK2, although these proteins have no amino acid homology to Cyclins 
(reviewed in (Gastwirt et al. 2007). RINGO binds to CDK1 and Cyclin B1 
separately but not the CDK1/Cyclin B1 complex and it can activate CDK1 in the 
absence of Cyclin B1 (Ferby et al. 1999). RGC-32 also binds and activates 
CDK1 activity in vitro (Badea et al. 2002). Interestingly, RGC-32 did not interact 
with the CDK1/Cyclin B1 complex in immunoprecipitation experiments carried 
out in HEK293T cells (Saigusa et al. 2007) raising the possibility that RGC-32 
competes with Cyclin B1 for CDK1 as found for RINGO/Speedy proteins 
(reviewed in (Gastwirt et al. 2007). Our in vitro pull-down assays showed that 
RGC-32 only interacts with CDK1, but not Cyclin B1 in B cells (Badea et al. 
2002) suggesting it may activate CDK1 in a cyclin-independent manner like 
RINGO/Speedy protein. To further confirm our conclusion, surface plasmon 
resonance (SPR) is being carried out in University of Newcastle is being done 
as part of a collaboration with Professor Jane Endicott and Dr. Nick Brown. SPR 
provides a way to observe protein-protein interactions in real time. Initial 
experiments have indicated that RGC-32 binds to CDK1 at much higher affinity 
than the CDK1-Cyclin B complex. These experiments also confirmed that RGC- 
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32, unlike RINGO, seems to have specificity for CDK1 as no binding to CDK2 
was detected.   
 
In vivo and in vitro RINGO was found to activate CDK1 independent of the 
phosphorylation of threonine 161 in the activation loop on CDK1 (Ferby et al. 
1999, Karaiskou et al. 2001). Further experiments showed RINGO could bind 
and activate CDK2 in the absence of cyclin and independent of threonine 160 
phosphorylation (Karaiskou et al. 2001, Porter et al. 2002). So it would be 
interesting to test if RGC-32 activates CDK1 through a mechanism alleviating 
the requirement for activation by CDK-activating kinase (CAK).  
 
CDK1 has also been shown to bind other proteins to control critical cell cycle 
events, e.g. Cyclin-dependent kinase subunit (Cks). Cks protein was identified 
in a screen for genes that can suppress the termperature-sensitive phenotype 
of CDK1 alleles(Hayles et al. 1986). Cks proteins bind to CDKs and Cyclins 
(Zhang et al. 2004). Cks proteins enhance the phosphorylation of selected 
CDK1 substrates in mitosis (Patra et al. 1999). Structural studies have 
determined the structures of Cks with CDK1 alone and CDK1/Cyclin B complex 
(Brown et al. 2015). It is possible that RGC-32 could bind to CDK1 alone and 
CDK1/Cyclin B1 like Cks.  
 
6.2 What is the role of cellular localisation of RGC-32 in 
recruitment of CDK1, Plk1 or Spc24? 
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In U-87 MG cells, ectopically expressed RGC-32 protein is located in the 
cytoplasm during interphase with the strongest signal around the nuclear 
membrane (Saigusa et al. 2007). In prophase, RGC-32 protein levels increase 
at the centrosome and in prometaphase and metaphase they reach maximal 
levels at the centrosome and spindle poles. During telophase and cytokinesis 
RGC-32 protein levels remain low in centrosome (Saigusa et al. 2007). These 
data is consistent with a role of RGC-32 in mitotic progression.  
 
RGC-32 interacts with the centrosome-associated polo-like kinase (Plk1) and is 
phosphorylated by Plk1 in vitro (Saigusa et al. 2007). Our in vitro pull-down 
assays showed that GST-RGC-32 interacted with Plk1 in B cells and further we 
mapped the potential domain on RGC-32 which is crucial for the interaction. 
Plk1 is a key regulator in mitosis (Barr et al. 2004) and expression and kinase 
activity of it has been shown to elevate in many kinds of cancers (Dietzmann et 
al. 2001, Takai et al. 2005). It is possible that RGC-32 may regulate the cell 
cycle through the interaction with Plk1. Cytoplasmic linker protein (CLIP) 170 
promotes the localisation of Plk1 at kinetochore in early mitosis through a Polo-
Box domain (Amin et al. 2014) and Plk1 localises at kinetochores in 
prometaphase to stabilise the kinetochore and microtubule attachment (Liu, 
Davydenko and Lampson 2012). During cell division, chromosome segregation 
is dependent on the kinetochore-microtubule attachment on the mitotic spindle, 
which progresses chromosome alignment (Tanaka, Stark and Tanaka 2005, 
Tanaka 2012, Tanaka 2013). It would be interesting to test whether RGC-32 
localises to kinetochore and investigate the role of RGC-32 in the recruitment of 
Plk1 to kinetochore. We mapped the regions of interaction between RGC-32 
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and Plk1 by in vitro pull-down assays. RGC-32 deletion which lacks the 
interaction regions with Plk1 could be fused to a fluorescent marker then 
transfected into cells to visualise its expression and localisation using 
fluorescent microscope. 
 
During the course of this study, we identified the third predicted α-helix of RGC-
32 as having homology to a receptor motif in the N terminus of the histone-fold 
protein Cnn1 from Saccharomyces cerevisiae using HHpred. This receptor motif 
is required for the association of Cnn1 with Spc24-25 heterodimer (Schleiffer et 
al. 2012). We showed that RGC-32 interacts with Spc24 in pull-down assays 
suggesting RGC-32 might play a role in kinetochore assembly or in recruiting 
kinases there. Three conserved hydrophobic residues phenylalanine 69, lysine 
70 and 73 in Cnn1 are required for its interaction with Spc24-25 as these 
residues face the hydrophobic pocket of Spc24-25 globular domain (Malvezzi et 
al. 2013). Interestingly these three residues were present in the third α-helix of 
RGC-32. The structure of the budding yeast Spc24-25 and Cnn1 interaction has 
been deposited in the Protein Data Bank with accession code 4GEQ (Malvezzi 
et al. 2013). We substituted those three conserved residues (phenylalanine 69, 
lysine 70 and 73) in Cnn1 by corresponding amino acids in RGC-32 to model 
RGC-32 in the structure with Spc24-25 (Figure 6-1). The substitution of RGC-32 
could still fit in the hydrophobic pocket of Spc24-25 globular domain. Next, we 
could mutate RGC-32 on these three residues and determine whether they are 
required for the interaction of RGC-32 and Spc24 using in vitro pull-down 
assays. 
6-155 
 
 
 
 
 
 
Figure 6-1. Structural analysis by substituting amino acids on Cnn1 with corresponding 
amino acids on RGC-32. 
A. and B. Close-up view of the Cnn1 and Spc24-25 interaction network (Accession number 4GEQ) 
(Malvezzi et al., 2013). The secondary structure of Cnn1, Spc24 and Spc25 is shown as orange, blue and 
grey respectively. C. and D. Amino acids on Cnn1 were substituted by corresponding amino acids on 
RGC-32. These amino acids are present in the third α-helical of RGC-32 which is identified to be 
homologous to the N-terminus of Cnn1.  
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CDK1 phosphorylation of the N terminus of CENP-T has been shown to play a 
role in kinetochore assembly in human cells (Gascoigne et al. 2011). Malvezzi 
et al. have shown that CDK1 phosphorylation of the Cnn1 N terminus is not 
required for the interaction between Spc24-25 and Cnn1 (Malvezzi et al. 2013). 
So it would be interesting to investigate if CDK1 could phosphorylate the N 
terminus of RGC-32 which is the homologue with Cnn1. It has been shown that 
RGC-32 mutation at threonine 91 abolishes the CDK1-mediated 
phosphorylation and leads to loss of CDK1 kinase enhancing activity (Badea et 
al. 2002). Interestingly, threonine 91 on RGC-32 is near the potential interaction 
helix of RGC-32 and Spc24-25. Next, we would investigate whether mutation of 
RGC-32 at threonine 91 is required for the interaction of RGC-32 and Spc24-25 
using pull-down assays. It is possible that phosphor status of RGC-32 could 
ensure that it interact stably with the kinetochore and spindle only at the correct 
time during mitosis.  
 
6.3 Is RGC-32 an oncogene or tumour suppressor? 
Overexpression of RGC-32 in the OLG-C6 glioma cell line leads to an increase 
in DNA synthesis in response to serum growth factors (Badea et al. 1998) and 
leads to S-phase and G2/M entry in smooth muscle cells (Badea et al. 2002). 
RGC-32 mRNA expression was up-regulated in breast cancer (Kang et al. 2003, 
Fosbrink et al. 2005), colon cancer (Fosbrink et al. 2005), lung cancer (Fosbrink 
et al. 2005), ovarian cancer (Donninger et al. 2004), stomach cancer (Fosbrink 
et al. 2005). This evidence indicates that RGC-32 is an oncogene. Other studies 
however, point to a role for RGC-32 as a tumour suppressor. RGC-32 gene was 
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absent in glioma cell lines and restoration of it caused the suppression of cell 
growth and overexpression of its protein delayed mitotic progression in HeLa 
cells (Saigusa et al. 2007).  
 
Our previous data showed that stable overexpression of RGC-32 alone is 
sufficient to disrupt the G2/M checkpoint in the EBV-negative B cell line DG75 
and BJAB (Schlick et al. 2011). I generated new cell lines expressing inducible 
RGC-32 for further investigation of RGC-32 function. It has been shown that 
RGC-32 directly binds to CDK1 and increases its activity by pull-down assay in 
vitro and immunoprecipitation in vivo (Badea et al. 2002). It is interesting to 
investigate whether cells overexpressing RGC-32 still can overcome G2/M 
checkpoint when the CDK1 activity is inhibited by CDK1 inhibitor e.g. 1NM-PP1. 
1NM-PP1 is a cell-permeable inhibitor of kinases that have been mutated by a 
single base substitution to become analogue sensitive compared to wild type 
kinases (Cayman chemical CAS 221244-14-0). It can inhibit the kinase activity 
of CDK1.  
 
6.4 What is the role of RGC-32 in EBV transformation? 
RGC-32 expressed at the RNA level in many different human tissues including 
artery, bladder, brain, breast, cervix, colon, heart, kidney, lung, liver, lung and 
pancreas. RGC-32 overexpressed at the RNA level in multiple human tumours 
including bladder, breast, colon, lung, prostate and ovaries (Kang et al. 2003, 
Donninger et al. 2004, Fosbrink et al. 2005). Our previously data has shown 
that RGC-32 mRNA expression is significantly higher in Latency I BL cell lines 
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and in some EBV-negative cell lines compared to latency III cell lines (Schlick et 
al. 2011). It is possible that EBV latency III gene products play a role in the 
regulation of RGC-32.  
 
Further evidence indicates RUNX genes also play a role in regulation of RGC-
32 expression. Therefore we summarised the regulation of RGC-32 mRNA 
expression by EBNAs and RUNX (Figure 6-2). EBNA 2 downregulates RGC-32 
expression in EBV-negative B cell line (Maier et al. 2006). EBNA 3A, 3B and 3C 
activate RGC-32 expression in LCLs (Hertle et al. 2009, Skalska et al. 2013, 
White et al. 2010). Our previous data shows that RGC-32 mRNA expression in 
human B cells is activated by RUNX1c (Schlick et al. 2011). Also our previous 
data has revealed RUNX gene regulation is controlled by the EBNAs in EBV-
infected cells (Gunnell et al. 2016). EBNA 2, 3B and 3C activate RUNX3 
expression (Gunnell et al. 2016). EBNA 2 activates, however EBNA 3B and 3C 
repress the expression of RUNX1 (Gunnell et al. 2016). RUNX 3 represses 
RUNX1 expression (Gunnell et al. 2016). EBNA 3A activates the expression of 
RUNX1 in LCLs (White et al. 2010) and EBNA 3B activates the expression of 
RUNX1 in LCLs (Hertle et al. 2009). It suggests that the expression of RGC-32 
is a consequence of collaborative working of EBV encoded EBNAs and RUNX. 
 
Although a number of microarray analyses have been done on RGC-32 mRNA 
expression, these studies do not show whether RGC-32 mRNA expression 
changes leads to a change in protein expression. Surprisingly our previous data 
has shown that RGC-32 protein expression is not consistent with its mRNA  
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Figure 6-2. RGC-32 gene regulation by the EBNAs and RUNX (modified from Gunnell et 
al., 2016).  
EBNA 2 downregulates RGC-32 expression and EBNA 3A, 3B and 3C upregulate RGC-32 expression. 
RUNX1 upregulates RGC-32 expression. EBNA 2, 3B and 3C activate RUNX3 expression by binding to a 
distal upstream super-enhancer. Then RUNX3 represses RUNX1 transcription by binding to the RUNX1 
P1 promoter. The activation of RUNX1 transcription by EBNA 2 is through an upstream super-enhancer 
and cell type specific. The repression of RUNX1 transcription is also cell type specific. Total RUNX1 
expression depends on the balance between the expression of RUNX1 which drives RUNX1 repression, 
EBNA 2 activation and EBNA 3B and 3C repression which are controlled by super-enhancer binding.  
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expression in EBV-positive cell lines latency I and latency III due to the blocking 
of its translation at a post-initiation stage in latency I cells (Schlick et al. 2011). It 
is still unclear how RGC-32 protein expression is regulated in EBV-transformed 
cells. Although the microarray data have suggested RGC-32 expression 
promotes tumour development, it would be still too early to draw any conclusion 
in the investigation of the role of RGC-32 in EBV transformation.  
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7 Appendices 
7.1 Antibodies 
Antibody Host Dilution Informaiton Company/Cat. No. 
Anti RGC32 Rabbit 1:500 Polyclonal Eurogentec 
Anti CDK1 Mouse 1:500 Monoclonal Invitrogen/33-1800 
Anti CDK1 Mouse 1:1000 Monoclonal Santa Cruz/sc-54 
Anti Cyclin B1 (GNS1) Mouse 1:1000 Monoclonal Santa Cruz/sc-245 
Anti CDK2 (D-12) Mouse 1:3000 Monoclonal Santa Cruz/sc-6248 
Anti Plk1 Mouse 1:1000 Monoclonal abcam/ab14210 
Anti Spc24 Rabbit 1:500 Polyclonal abcam/ab157184 
Anti EBNA 1  
(M. Stacey serum) Human 1:200 Polyclonal Gift from M. Rowe. 
Anti actin Rabbit 1:5000 Polyclonal Sigma 
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7.2 Plasmids 
Plasmid Information Reference/ 
    Company 
pET16  
RGC-32 
RGC-32 was cut of pFLAG RGC-32 as an 
SalI/BamHI fragment and cloned into pET16b 
(Sigma) digested with XhoI/BamHI. 
Sigma and  
created by  
Helen Webb 
pET28  
Cyclin B1 
Cyclin B1 (residues 165-433) was amplified 
by PCR and cloned into 
pET28a (Novagen). 
Gift from E.  
Petri (Petri et 
al., 2007)  
pGEX   
RGC-32 
RGC-32 was amplified from pFLAG RGC-32 
and cloned into pGEX-6P3  
as a BamHI/NotI fragment. 
Created by  
Lina Chen 
pGEX  
RGC-32  
T91A 
RGC-32 was amplified from pFLAG RGC-32 
T91A and cloned into pGEX-6P3 as a 
BamHI/ NotI fragment. 
Created by  
Lina Chen 
pFLAG  
RGC-32 
RGC-32 was amplified from BJAB E3C-4 
(Wang et al., 1990) cDNA and cloned into 
pFLAG-CMV-2 as an XbaI/BamHI fragment. 
Created by  
Helen Webb 
pGEX   
RGC-32 
1-25 
RGC-32 (residues 1-25) was amplified from 
pFLAG RGC-32 and cloned into pGEX-6P3 
as a BamHI/XhoI fragment. 
Created by  
Lina Chen 
pGEX  
RGC-32  
1-50 
RGC-32 (residues 1-50) was amplified 
from pFLAG RGC-32 and cloned into pGEX-
6P3 as a BamHI/XhoI fragment. 
Created by  
Lina Chen 
pGEX  
RGC-32  
1-75 
RGC-32 (residues 1-75) was amplified from 
pFLAG RGC-32 and cloned into pGEX-6P3 
as a BamHI/XhoI fragment. 
Created by  
Lina Chen 
pGEX  
RGC-32  
1-100 
RGC-32 (residues 1-100) was amplified 
from pFLAG RGC-32 and cloned into 
pGEX-6P3 as a BamHI/XhoI fragment. 
Created by  
Lina Chen 
pMA  
RGC32  
mutant  
for CDK1 
binding 
RGC-32 mutant (F68A, F70A) was inserted 
into pMA as a KpnI/SacI fragment. 
Life 
technologies 
pMA  
RGC32  
mutant  
RGC-32 mutant (Y33A, K41E, R42E, R43E) 
was inserted into pMA as an SfiI/SfiI 
fragment. 
Life 
technologies 
for Plk1 
binding 
   
pGEX  
RGC-32 
mutant  
for CDK1 
binding 
RGC-32 mutant (F68A, F70A) was cut of 
pMA RGC-32 mutant for CDK1 binding and 
cloned into pGEX-6P3 as a BamHI/NotI 
fragment. 
Created by  
Lina Chen 
pGEX  
RGC-32 
mutant for  
Plk1 binding  
RGC-32 mutant (Y33A, K41E, R42E, R43E) 
was cut of pMA RGC-32 mutant for Plk1 
binding and cloned into pGEX-6P3 as a 
BamHI/NotI fragment. 
Created by  
Lina Chen 
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pRTS-1  
RGC-32 
RGC-32 was cut of pUC19 RGC-32 as an 
SfiI/SfiI fragment and cloned into pRTS-1 
(Georg W. Bornkamm) digested by SfiI. 
Created by  
Lina Chen 
pSG5 
EBNA 2 
The EBNA 2 open reading frame of EBV 
strain W91 under the control of the SV40 
early promoter in pSG5 vector 
Gift from M. 
Rowe  
pGL2  
RGC-32  
1.2 kb fragment (approximately from -1150 to 
+62 relative to predicted transcription start 
site) of the RGC-32 promoter was amplified 
from genomic DNA and cloned into pGL2 
Basic cut with HindIII/KpnI. 
Created by 
Helen Webb 
pGL3  
RGC-32  
The RGC-32 promoter fragment was but with 
HindIII/KpnI out of pGL2 RGC-32 and cloned 
into a pGL3 Basic vector. 
Created by 
Sandra Schlick 
pGL3  
RGC-32  
E2 
The RGC-32 enhancer element 2 
(approximately 600 bp) was amplified from 
genomic DNA and cloned into pGL3 RGC-32 
cut with KpnI. 
Created by  
Lina Chen 
pGL3  
RGC-32  
E4 
The RGC-32 enhancer element 4 
(approximately 700 bp) was amplified from 
genomic DNA and cloned into pGL3 RGC-32 
cut with KpnI. 
Created by  
Lina Chen 
pGL3  
RGC-32  
E6 
The RGC-32 enhancer element 6 
(approximately 800 bp) was amplified from 
genomic DNA and cloned into pGL3 RGC-32 
cut with KpnI. 
Created by  
Lina Chen 
pGL3  
RGC-32  
E8 
The RGC-32 enhancer element 8 
(approximately 700 bp) was amplified from 
genomic DNA and cloned into pGL3 RGC-32 
cut with KpnI. 
Created by  
Lina Chen 
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7.3 PCR primers 
Gene Sequence 
RGC-32 primers for making 
pGEX RGC-32 or pGEX  
RGC-32 T91A 
 
MW 594 (forward primer) 
MW 525 (reverse primer) 
 
 
 
 
GCG GAT CCT CTA GAA TGA AGC CGC CC 
CGG CGG CCG CTC ACA TAC TTG CTA AAG T 
RGC-32 primers for making 
pGEX RGC-32 1-25  
 
MW 594 (forward primer)  
MW 730 (reverse primer) 
  
 
 
GCG GAT CCT CTA GAA TGA AGC CGC CC 
GCT CGA GTC AGG GCG ACG CGA AGT CGG CCA G 
RGC-32 primers for making 
pGEX RGC-32 1-50  
 
MW 594 (forward primer) 
MW 731 (reverse primer) 
  
 
 
GCG GAT CCT CTA GAA TGA AGC CGC CC 
GCT CGA GTC AGT CGC TGA CAC TGG CGC TGC T 
RGC-32 primers for making 
pGEX RGC-32 1-75  
 
MW 594 (forward primer)  
MW 732 (reverse primer) 
  
 
 
GCG GAT CCT CTA GAA TGA AGC CGC CC 
GCT CGA GTC ACA GTT TTT CAT CAC TGA AGC T 
RGC-32 primers for making 
pGEX RGC-32 1-100  
 
MW 594 (forward primer)  
MW 733 (reverse primer) 
  
 
 
GCG GAT CCT CTA GAA TGA AGC CGC CC 
GCT CGA GTC ATG TGT CTC CTA ATT TAG CTT T 
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7.4 qPCR primers 
Gene Sequence 
RGC-32 ChIP qPCR E1   
MW 629 (forward primer) GCC AGT GTC TCG CAT GAA 
MW 630 (reverse primer) GTT GGT GCA CCT TCA GAC AG 
RGC-32 ChIP qPCR E2   
MW 631 (forward primer) CCA GCA TGA CAG ATG GCT TA 
MW 632 (reverse primer) AGG CTC CTC ATT GGC CTT A  
RGC-32 ChIP qPCR E3   
MW 633 (forward primer) GTG ATC AGC CAG CAA CAC AT 
MW 634 (reverse primer) AGC CGG ACA TCC TGT TCT T 
RGC-32 ChIP qPCR E4   
MW 635 (forward primer) GAT AGA GAG CGG AGG TGT GG 
MW 636 (reverse primer) CCG TGG CTA TGA AGG ATA CC 
RGC-32 ChIP qPCR E5   
MW 637 (forward primer) GGC CAG CTT CCT GTG TGT A 
MW 638 (reverse primer) CTC CGT GGA ACC TTA CTT GG 
RGC-32 ChIP qPCR E6   
MW 639 (forward primer) GAG CCA TGA TGT CAC TCC AA 
MW 640 (reverse primer) CTT CAG ATA AGC CAG AAG GTC AA 
RGC-32 ChIP qPCR E7   
MW 641 (forward primer) GTG ATC TTG GCT CAC TGC AA 
MW 642 (reverse primer) TAG CCA GGC ATA GTG GTG TG 
RGC-32 ChIP qPCR E8   
MW 774 (forward primer) ACA CCT GAA GAG CCA CTT CTC T 
MW 775 (reverse primer) CTG GCT GAG CAG CAC TGA  
RGC-32 ChIP qPCR E9   
MW 776 (forward primer) AGA GGG CAG AAG GGA CAT ATT 
MW 777 (reverse primer) TGT GTC AAA TCA AGT ATA CCA AAG G 
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